Archived Medical News Stories

RSSArchived Drug Trial News Stories - 2011

Date Title Comments Rating
2011-12-31 Additional financing to fund Advaxis' cervical cancer trials 0 None
2011-12-30 FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer 0 None
2011-12-29 GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer 0 None
2011-12-29 Bevacizumab delays disease progression in ovarian cancer 0 None
2011-12-29 Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL 0 None
2011-12-28 Critical considerations for adenovirus-based HIV vaccine trials 0 None
2011-12-28 IL-1 gene inactivation may reduce severe clinical complications of atherosclerosis 0 3
2011-12-27 CEL-SCI to expand Multikine Phase III trial in head and neck cancer 0 None
2011-12-26 Initial results from 22nd Century's X-22 Phase II-B smoking cessation trial 0 None
2011-12-23 Correcting anemia can preserve kidney function in many transplant recipients 0 None
2011-12-23 Top-line results from Noven's LDMP Phase 3 clinical study on menopausal VMS 0 None
2011-12-23 Abbott commences Esprit drug eluting BVS trial in peripheral artery disease 0 None
2011-12-23 ViroPharma to acquire Meritage 0 None
2011-12-23 Enrollment complete in two Anacor's tavaborole Phase 3 trials on onychomycosis 0 None
2011-12-23 Science journal names UNC HIV prevention study as 2011 Breakthrough of the Year 0 None
2011-12-23 ThromboGenics submits ocriplasmin BLA with FDA to treat symptomatic VMA 0 3
2011-12-23 EpiCept receives FDA approval to commence AmiKet Phase III trial for CIPN 0 None
2011-12-22 Azithromycin shows promise against trachoma-related blindness 0 None
2011-12-22 AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC 0 None
2011-12-22 Researchers evaluate Clade C HIV envelope protein in Phase I trial 0 None
2011-12-21 Denali Concrete Management initiates enrollment in CF101 phase 3 study for Dry Eye Syndrome 0 None
2011-12-21 Chlorthalidone may reduce risk of death in patients with systolic hypertension 0 None
2011-12-21 Antihypertensive drug therapy associated with longer life expectancy 0 None
2011-12-21 University of Western Ontario receives FDA approval to begin SAV001 HIV trial 0 None
2011-12-21 Vacc-4x nasal vaccine can effectively treat HIV 0 None
2011-12-21 UCB initiates EXXELERATE study in rheumatoid arthritis 0 None
2011-12-21 Takeda enters agreement to acquire Intellikine 0 None
2011-12-20 DHEA hormone may help a woman's menopausal symptoms, sex life 0 None
2011-12-20 Top-line results from Genzyme's teriflunomide and Rebif Phase III comparison trial on RMS 0 None
2011-12-20 Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 study on MDD 0 None
2011-12-20 Impax commences IPX159 Phase IIb trial in Restless Legs Syndrome 0 None
2011-12-19 Atox Bio to advance AB103 Phase 2 study with $3.25M financing 0 None
2011-12-19 Phase I clinical study of Selexys SelG1 for sickle cell disease completed 0 None
2011-12-19 ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS 0 None
2011-12-19 Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia 0 None
2011-12-19 GSK initiates rhACE2 phase IIa study for Acute Lung Injury 0 None
2011-12-19 Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain 0 None
2011-12-19 Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial 0 None
2011-12-17 Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma 0 None
2011-12-17 Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE 0 None
2011-12-17 Immediate ART appears preferable to deferring treatment among recently infected HIV patients 0 None
2011-12-15 Positive results from Hatchtech's DeOvo Phase 2b trial on head lice 0 None
2011-12-15 Cereblon protein now holds hope in fight against multiple myeloma 0 None
2011-12-15 Vaginal progesterone safe and effective in preventing preterm birth 0 None
2011-12-15 Vaginal progesterone reduces rate of preterm birth and neonatal complications 0 None
2011-12-15 AtheroNova establishes clear development plan for AHRO-001 after positive FDA feedback 0 None
2011-12-15 JHN to initiate new Phase I immunotherapy trial in glioblastoma 0 None
2011-12-15 Isis announces addition of three new drug development candidates 0 None
2011-12-15 Ganitumab shows promise in early-phase trials for metastatic pancreatic cancer 0 None
2011-12-14 Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL 0 None
2011-12-14 Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain 0 None
2011-12-14 Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM 0 None
2011-12-14 Maraviroc reduces incidence of GvHD in blood cancer patients after ASCT 0 None
2011-12-14 CTI, Chroma announce final results from tosedostat phase II study on AML 0 None
2011-12-14 JDRF initiates enrollment in metformin clinical study for type 1 diabetes 0 None
2011-12-14 Positive results from Aestus' ATx08-001 Phase II study on post-herpetic neuralgia 1 None
2011-12-14 ImmusanT secures $20M in Series A financing 0 None
2011-12-14 Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients 0 None
2011-12-13 Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis 0 None
2011-12-13 Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis 0 None
2011-12-13 ISIS-FXIRx reduces Factor XI activity without bleeding in healthy volunteers 0 None
2011-12-13 S*BIO announces results from pacritinib Phase 2 study on myelofibrosis 0 None
2011-12-13 Combination of bortezomib and panobinostat shows promise against advanced MM 0 None
2011-12-13 Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types 0 None
2011-12-13 Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS 0 None
2011-12-13 Plexxikon announces scientific findings from PLX3397 preclinical studies on AML 0 None
2011-12-13 Three-drug combination therapy appears to be effective for newly diagnosed MM patients 0 None
2011-12-13 Geron commences GRN1005 Phase 2 trial in breast cancer 0 None
2011-12-12 Soligenix reports results from orBec Phase 2 trial on acute GVHD 0 None
2011-12-12 Treatment with leukemia patients' own cells may prevent infections after chemotherapy 0 None
2011-12-12 Celgene announces interim results of REVLIMID study on CLL 0 None
2011-12-12 Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD 0 None
2011-12-12 Research examines novel treatment techniques for hemophilia B, VTE 0 None
2011-12-12 Onconova announces data from five rigosertib clinical trials on MDS 0 None
2011-12-12 Re-treatment with rituximab may benefit patients with LTB follicular lymphoma 0 3
2011-12-12 PCI-32765 is highly active and well tolerated in patients with CLL 0 None
2011-12-12 Onyx announces data from three carfilzomib studies on RRMM 0 None
2011-12-12 New findings from Micromet's blinatumomab phase 1 trial on DLBCL 0 None
2011-12-12 New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting 0 None
2011-12-12 Syndax announces data from entinostat phase 2 study on HL 0 None
2011-12-12 SCRI to present findings of blood cancer trials at 53rd ASH annual meeting 0 None
2011-12-12 Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study 0 None
2011-12-12 Obese women with early-stage HER2-positive breast cancer may have poorer outcomes 0 None
2011-12-12 Celgene announces results from azacitidine Phase 1 study on AML 0 None
2011-12-12 PCI-32765 produces durable remissions in Phase I/II CLL clinical trial 0 None
2011-12-12 New data from TetraLogic's TL32711 study on AML presented at 53rd ASH meeting 0 None
2011-12-12 ACE inhibitors, ARBs have different effects on heart health of dialysis patients 0 3
2011-12-12 Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV 0 None
2011-12-12 Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting 1 None
2011-12-09 Science examines HIV prevention trials, challenges to implementing new strategies 0 None
2011-12-09 Trastuzumab improves long-term outcomes in obese patients with HER2-positive breast cancer 0 None
2011-12-09 Shorter, effective treatment for latent TB infection 0 None
2011-12-09 Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium 0 None
2011-12-09 Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV 0 None
2011-12-09 VIVUS announces results of Qnexa clinical study on cardiometabolic disease 0 None
2011-12-09 Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC 0 None
2011-12-09 Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout 0 None
2011-12-09 Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM 0 None
2011-12-09 ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy 0 None
2011-12-08 Combination of two anti-estrogen drugs extends survival time of women with breast cancer 0 None
2011-12-08 Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer 0 None
2011-12-08 Inviragen presents DENVax Phase 1 trial results on dengue at ASTMH annual meeting 0 None
2011-12-08 PrEP shows promise against HIV infection 0 None
2011-12-08 Notch inhibitor appears to treat breast cancer 0 None
2011-12-08 Influenza shot boosts immune response in pregnant women, protects neonatal babies 0 None
2011-12-08 Combination treatment extends lives of women with metastatic breast cancer 0 None
2011-12-08 Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC 0 None
2011-12-08 Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer 0 None
2011-12-08 Positive results from Pearl Therapeutics' PT001 Phase 2b trial on COPD 0 None
2011-12-07 ZIOPHARM receives European patent allowance for palifosfamide to treat cancer 0 None
2011-12-07 FDA modifies requirements of Amgen's Nplate REMS Program 0 None
2011-12-06 Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain 0 None
2011-12-06 PDUFA goal date of NDA for Protalix's taliglucerase alfa extended 0 None
2011-12-06 Study reveals mechanism of action of laquinimod in patients with RRMS 0 None
2011-12-06 VIVUS announces multiple abstracts on avanafil presented at ESSM meeting 0 None
2011-12-06 Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder 0 None
2011-12-05 EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting 0 None
2011-12-05 Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease 0 None
2011-12-05 Unigene acquires exclusive worldwide rights to oral PTH program from GSK 0 None
2011-12-05 NanoViricides submits pre-IND Meeting Request for FluCide to FDA 0 None
2011-12-05 Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD 0 5
2011-12-05 Zalicus commences Z160 Phase 1 clinical trial for pain 0 None
2011-12-05 Post-baseline vision data from Lundbeck's Sabril patient registry presented at AES meeting 0 None
2011-12-03 CDER, Shire enter agreement for ProAmatine clinical trial to treat symptomatic orthostatic hypotension 0 None
2011-12-03 Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease 0 None
2011-12-03 Progesterone can benefit women with catamenial seizures: Study 0 None
2011-12-03 Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint 0 5
2011-12-03 Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV 0 None
2011-12-02 Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV 0 None
2011-12-02 John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting 0 None
2011-12-02 Scottsdale resident donates $1 million to TGen pancreatic cancer initiative 0 None
2011-12-02 Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis 0 None
2011-12-02 AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab 0 None
2011-12-01 ADVENTRX, FDA discuss ANX-188 development plans for treatment of sickle cell crisis 0 None
2011-12-01 Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus 0 None
2011-12-01 Enrollment complete in Ceregene's CERE-120 Phase 2b trial for Parkinson's 0 None
2011-12-01 Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome 0 None
2011-12-01 Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma 0 None
2011-12-01 Statens Serum Institut, Aeras initiate new candidate TB vaccine Phase I trial 0 None
2011-12-01 Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer 0 None
2011-11-30 Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors 0 None
2011-11-30 Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch 0 None
2011-11-30 Genentech announces results from pertuzumab studies on HER2-positive breast cancer 0 None
2011-11-30 BioMarin commences GALNS Phase 2 study in mucopolysaccharidosis IVA 0 None
2011-11-29 Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection 0 None
2011-11-29 FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation 0 None
2011-11-29 Testing of vaginal gel for HIV prevention halted after interim results showed no difference from placebo 0 None
2011-11-29 Selcia completes 14C radiolabelled API projects for clients 0 None
2011-11-29 VOICE continues testing daily use of ARV Truvada among women in sub-Saharan Africa 0 None
2011-11-28 Tenofovir gel no more effective than placebo gel in preventing HIV 0 None
2011-11-28 FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia 0 None
2011-11-28 Inviragen commences DENVax Phase 2 trial for dengue 0 None
2011-11-28 Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD 0 None
2011-11-28 Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A 0 None
2011-11-28 Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China 0 None
2011-11-28 Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia 0 None
2011-11-28 Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib 0 None
2011-11-28 Inspiration initiates second OBI-1 phase III clinical trial in congenital hemophilia A with inhibitors 0 None
2011-11-25 Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine 0 None
2011-11-23 Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC 0 None
2011-11-23 Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits 0 None
2011-11-22 Arginine may reactivate T-cells in patients with glioblastoma 0 None
2011-11-22 Study: Vaccine development efforts currently focus on incidence rather than mortality rates 0 None
2011-11-21 Nature Medicine publishes dexpramipexole Phase 2 ALS study results 0 None
2011-11-21 Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy 0 None
2011-11-21 SAFC commences process validation activities for Oncolytics' REOLYSIN 0 None
2011-11-21 PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic 0 4
2011-11-21 Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study 0 None
2011-11-21 Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated 0 None
2011-11-21 Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis 0 None
2011-11-21 Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention 0 None
2011-11-21 ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris 0 None
2011-11-21 EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis 0 None
2011-11-21 Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain 0 None
2011-11-20 Promising results from dexpramipexole phase 2 trial on ALS 0 None
2011-11-19 PEPFAR Scientific Advisory Board report offers six recommended research priorities 0 None
2011-11-19 Combo hormone therapy increases risk of breast cancer in women with new-onset tenderness 0 None
2011-11-18 Merrimack initiates MM-121 Phase 2 combination trial in metastatic NSCLC 0 None
2011-11-18 FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC 0 None
2011-11-18 FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin 0 None
2011-11-18 Tonix to initiate TNX-102 PK and BA study for fibromyalgia 0 None
2011-11-18 Inovio announces results from SynCon avian influenza vaccine Phase I study 0 None
2011-11-17 Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC 0 None
2011-11-17 Aurora kinase inhibitor may treat neuroendocrine prostate cancer 0 None
2011-11-17 Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial 0 None
2011-11-17 Mycophenolate mofetil superior to azathioprine for lupus nephritis 0 None
2011-11-17 New 2-DG-ABT combination cancer therapy triggers apoptosis 0 5
2011-11-17 Bionovo initiates Menerba Phase 3 trial in menopausal hot flashes 0 5
2011-11-16 Additional results from BioSante's LibiGel pK study on HSDD 0 None
2011-11-16 First clinical trial of dapivirine-maraviroc ring to treat HIV in women 0 None
2011-11-16 NIAID's ACTG and TB Alliance partner to complete moxifloxacin Phase III trial 0 None
2011-11-16 Rosuvastatin as effective as atorvastatin in reversing atherosclerosis 0 None
2011-11-16 Amgen's XGEVA delays onset of bone metastases in men with prostate cancer 0 None
2011-11-15 Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis 0 None
2011-11-15 Pneumococcal vaccine Prevnar13 effective in seniors 0 None
2011-11-15 Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome 0 None
2011-11-15 ProFibrix Fibrocaps effectively reduces bleeding in liver resection surgery 0 4
2011-11-15 POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs 0 1
2011-11-15 Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC 0 3
2011-11-15 Mesoblast reports positive Revascor Phase 2 heart failure trial results 0 None
2011-11-14 Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress 0 None
2011-11-14 Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial 0 None
2011-11-14 Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals 0 None
2011-11-14 Top-line results from Probiodrug's PQ912 Phase 1 SAD, MAD study for Alzheimer's disease 0 None
2011-11-14 A shot to lower 'bad' cholesterol 0 None
2011-11-14 Cerulean to present positive CRLX101 progression-free survival time results at 2011 AACR-NCI-EORTC 0 None
2011-11-14 Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012 0 None
2011-11-14 Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers 0 None
2011-11-14 Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints 0 None
2011-11-14 Amplification of ALK gene may drive rapid breast cancer metastasis 0 None
2011-11-14 Exelixis reports cabozantinib phase 2 trial data on bone metastases 0 None
2011-11-14 Feraheme as safe and effective as iron sucrose in patients with anemia, CKD 0 None
2011-11-14 New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference 0 None
2011-11-14 Patients with KRAS mutant NSCLC should respond well to antifolates 0 None
2011-11-14 Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD 0 None
2011-11-11 Ampion safe and effective for patients with nasal inflammation 0 None
2011-11-11 NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors 0 None
2011-11-11 Provectus announces data from Phase 2 PV-10 metastatic melanoma study 0 None
2011-11-10 Positive results from Alkermes VIVITROL addiction study 0 None
2011-11-10 Combination of azacitidine and entinostat shows promise against NSCLC 0 None
2011-11-10 Clinilabs to utilize NewCardio's QTinno in Phase I trial of new CNS drug 0 None
2011-11-09 Large-scale trials show HPV vaccine effective against multiple strains, could reduce need for screening 0 None
2011-11-09 Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis 0 5
2011-11-09 Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis 0 None
2011-11-09 EI-IC bypass surgery does not lower risk of stroke recurrence in patients with TIA 0 None
2011-11-09 Infinity third quarter total revenue increases marginally to $23.3 million 0 None
2011-11-09 First-ever phase 1 clinical trial of rectal HIV-prevention drug 0 None
2011-11-09 Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint 0 None
2011-11-09 Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV 0 None
2011-11-09 Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients 0 None
2011-11-09 Positive results from ChemoCentryx CCX354 Phase II study on RA 0 None
2011-11-09 Micromet's blinatumomab data to be reported at 53rd ASH annual meeting 0 None
2011-11-08 Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors 0 None
2011-11-08 Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis 0 None
2011-11-08 New results from BioCryst's BCX4208 Phase 2b gout study 0 None
2011-11-08 Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD 0 None
2011-11-08 MBL-HCV1 can reduce viral load in liver transplant patients 0 None
2011-11-08 First large-scale study to address treatment of prescription opioid addiction 0 None
2011-11-07 New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting 0 None
2011-11-07 Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting 0 None
2011-11-07 HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting 0 None
2011-11-07 NewCardio's automated cardiac safety solution selected by top pharma company for Phase I drug study 0 None
2011-11-07 ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment 0 None
2011-11-07 KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011 0 None
2011-11-07 Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism 0 None
2011-11-07 Abbott announces results from HUMIRA Phase 3 study on axSpA 0 None
2011-11-07 Encouraging results from SEEK's FLU-v Phase II study 0 None
2011-11-07 UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting 0 None
2011-11-07 Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011 0 None
2011-11-07 New data from Novartis' ACZ885 Phase III study on SJIA 0 None
2011-11-07 Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV 0 None
2011-11-07 New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA 0 None
2011-11-07 Rheumavax safe and feasible in treating RA 0 None
2011-11-07 New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout 0 None
2011-11-07 Vitamin D supplementation benefits people with lupus 0 None
2011-11-07 Children with polyarticular JIA benefit from early and aggressive therapy 0 None
2011-11-06 Final results from Vertex VX-509 Phase 2a study on RA 0 None
2011-11-06 New data from Santaris Pharma miravirsen Phase 2a trial on HCV 0 None
2011-11-06 Cystic fibrosis drug shows promise in trial 0 None
2011-11-05 Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting 0 None
2011-11-05 Sunovion reports positive results from ciclesonide nasal aerosol Phase III study for perennial allergic rhinitis 0 None
2011-11-05 Presidio Pharmaceuticals advances with its HCV antiviral drug discovery, development programs 0 5
2011-11-05 Results of Phase 2 program to develop NSAIDs to be reported at ACR annual meeting 0 None
2011-11-05 SCRIP honors Glenmark for business excellence and innovative R & D capabilities 0 None
2011-11-05 Daily intake of Souvenaid improves memory in people with mild AD 0 3.7
2011-11-05 Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder 0 None
2011-11-05 Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome 0 None
2011-11-04 Inhibitex third quarter revenue increases to $1.3 million 0 None
2011-11-04 Jennerex commences enrollment in JX-594 Phase 2b trial for HCC 0 None
2011-11-04 Final results from Vertex KALYDECO second of two Phase 3 studies on CF 0 None
2011-11-03 Senesco commences dosing in SNS01-T Phase 1b/2a clinical study for multiple myeloma 0 None
2011-11-03 Positive results from Clinuvel's US Phase II study of photoprotective drug, afamelanotide 0 None
2011-11-03 Abbott to highlight latest research findings on HUMIRA at ACR annual meeting 0 None
2011-11-03 Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board 0 None
2011-11-03 FEIBA drug safe and effective for patients with hemophilia A 0 None
2011-11-03 Ivacaftor drug improves lung function in people with cystic fibrosis 1 None
2011-11-03 Final results from Medivir's TMC435 phase IIb study on genotype-1 hepatitis C 0 None
2011-11-02 Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes 0 None
2011-11-02 PSTC, FNIH Biomarkers Consortium launch clinical study to improve detection of kidney injury 0 None
2011-11-02 Targeted antibiotic safe and effective for irritable bowel syndrome 0 None
2011-11-02 Vitamin D does not confer benefits against mortality in postmenopausal women 0 None
2011-11-02 Ocrelizumab drug holds promise for multiple sclerosis 1 5
2011-11-02 Takeda receives FDA approval for VELCADE sNDA to treat MM 0 None
2011-11-02 Positive results from DARA's DB959 Phase 1b study on type 2 diabetes 0 None
2011-11-01 Pharmasset initiates PSI-7977 Phase 3 program for HCV 2 None
2011-11-01 Studies on effectiveness of new HCV therapies presented at 76th ACG meeting 0 None
2011-11-01 NPS announces new data from GATTEX Phase 3 study on short bowel syndrome 0 None
2011-11-01 Teva reports data from QNASL studies on seasonal and perennial allergic rhinitis 0 None
2011-11-01 UCB to present new data on Cimzia at ACG annual scientific meeting 0 None
2011-10-31 Aspirin may reduce risk of bowel cancer by half: Study 0 None
2011-10-31 Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine 0 None
2011-10-31 Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers 0 None
2011-10-31 Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies 0 None
2011-10-31 Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors 0 None
2011-10-31 YM BioSciences announces results of nimotuzumab Phase II study on DIPG 0 None
2011-10-31 Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines 0 None
2011-10-31 HAL Allergy initiates PURETHAL Mites PHASE II study 0 None
2011-10-29 Ovarian cancer patients with many folate receptors benefit from new therapy 0 None
2011-10-29 Glitazone treatment does not cause side effects in patients with metastatic thyroid cancer 0 None
2011-10-29 Not too early to consider funding for, distribution of malaria vaccine 0 None
2011-10-29 Some experts question early release of RTS,S malaria vaccine trial data 0 None
2011-10-29 BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment 0 None
2011-10-28 Reasons for caution about experimental malaria vaccine 0 None
2011-10-28 Sulodexide drug fails to benefit diabetes patients with kidney disease 0 None
2011-10-28 Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers 0 None
2011-10-28 Diabetic patients with mild kidney disease may benefit from vitamin B6 derivative 0 None
2011-10-28 Regeneron announces positive results from sarilumab Phase 2b trial on RA 0 None
2011-10-27 Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint 0 None
2011-10-27 Gardasil vaccine safe and effective against anal cancer 0 None
2011-10-24 Biogen’s Multiple Sclerosis pill succeeds at a late phase clinical trial 0 2
2011-10-24 external Trigeminal Nerve Stimulation pediatric clinical trial for ADHD receives NeuroSigma funding 0 None
2011-10-24 Sustained 'vigilance and money' necessary to fight malaria 0 None
2011-10-24 Tenofovir gel confirmed to be effective against herpes in lab experiment, study shows 0 None
2011-10-24 FDA approves intraspinal injections in spinal cord stem cell ALS trial 0 5
2011-10-24 Lundbeck's ONFI receives FDA approval for treating seizures associated with Lennox-Gastaut syndrome 0 None
2011-10-24 European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation 0 None
2011-10-24 Zeaxanthin reduces risk for AMD 0 None
2011-10-24 Vertex initiates INCIVEK combination Phase 3b study for hepatitis C 0 None
2011-10-24 Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation 0 None
2011-10-24 Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer 0 None
2011-10-24 Mesoblast cleared to begin first phase 2 clinical trial for wet AMD 0 None
2011-10-24 Mirna, Silence enter agreement to assess delivery systems for novel microRNAs 0 None
2011-10-22 Pivotal pediatric clinical study comparing Q/LAIV to FluMist meets primary endpoint 0 None
2011-10-22 Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS 0 None
2011-10-22 Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial 0 None
2011-10-22 Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis 0 None
2011-10-22 Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA 0 None
2011-10-22 Janssen announces FDA label update approval for PREZISTA HIV tablets 0 None
2011-10-22 Additional data from Sanofi's quadrivalent inactivated influenza vaccine study 0 None
2011-10-22 Merz presents XEOMIN clinical data on dystonia at IDS 2011 0 5
2011-10-22 Positive top line results from Shire's LDX phase III study on ADHD 0 None
2011-10-22 NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis 0 None
2011-10-22 Much work remains to be done in fight against malaria 0 None
2011-10-22 Romark announces results from NT-300 Phase 2B-3 trial on influenza 0 None
2011-10-22 Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases 0 None
2011-10-22 Boehringer Ingelheim announces new data from hepatitis C virus portfolio 0 None
2011-10-21 Geron announces data from ongoing GRNOPC1 Phase 1 trial on spinal cord injury 0 None
2011-10-21 Genentech announces 96-week results from ocrelizumab Phase II study on RRMS 0 None
2011-10-21 OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer 0 None
2011-10-20 Starting HIV therapy within two weeks of TB treatment increases survival by 33% 0 None
2011-10-20 TGen collaborates with Samuel Oschin Comprehensive Cancer Institute for clinical trials 0 None
2011-10-20 Rituximab may alleviate chronic fatigue syndrome through B-lymphocyte depletion 0 5
2011-10-20 EMA, FDA endorse use of biomarkers in Alzheimer's drug trials 0 None
2011-10-20 Despite progress in malaria vaccine development, funding remains potential stumbling block 0 None
2011-10-20 Experimental vaccine halves risk of malaria in African children, results of large clinical trial suggest 0 None
2011-10-19 Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011 0 None
2011-10-19 Oral laquinimod shows promise against multiple sclerosis 0 5
2011-10-19 Topical corticosteroids show promise against bacterial corneal ulcers 0 None
2011-10-19 RTS,S vaccine reduces risk of severe malaria in African children 0 None
2011-10-18 First results from phase 3 malaria vaccine candidate trial 0 None
2011-10-18 FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B 0 5
2011-10-18 Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes 0 None
2011-10-18 Natroba effective against head lice and nits 0 None
2011-10-18 Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer 0 None
2011-10-18 Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer 0 None
2011-10-18 ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis 0 None
2011-10-15 ABI provides clinical update on company activities 0 None
2011-10-15 Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds 0 None
2011-10-14 Four companies receive NIAID contracts to develop broad-spectrum therapeutics 0 None
2011-10-14 NIH-funded study to evaluate rescue medications for victims of toxic gases 0 None
2011-10-14 USAID award supports study of SILCS diaphragm plus tenofovir gel on HIV, HSV 0 None
2011-10-14 New dual drug combinations in development for various cancers 0 None
2011-10-14 Merck announces results from ISENTRESS Phase III combination study on HIV-1 0 None
2011-10-14 Micromet receives FDA feedback on blinatumomab registration for R/R ALL 0 None
2011-10-14 Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV 0 None
2011-10-14 JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM 0 None
2011-10-14 Baxter commences BAX 111 Phase III trial in von Willebrand disease 0 None
2011-10-14 InnaVirVax announces Phase I/IIa clinical trial authorization for its VAC-3S HIV vaccine 0 None
2011-10-13 Top-line results from POZEN's PA32540 Phase 3 trial on aspirin-associated gastric ulcers 0 None
2011-10-13 Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction 0 None
2011-10-13 EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL 0 None
2011-10-12 Intellikine commences INK1117 Phase I dose escalation study in cancer 0 None
2011-10-12 Vitamin E supplements linked with increased risk of prostate cancer 0 None
2011-10-12 Daily vitamin E supplementation may increase risk of prostate cancer 0 None
2011-10-12 FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy 0 None
2011-10-12 AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01 0 None
2011-10-12 Shield commences two ST10 Phase 3 studies in iron deficiency anaemia 0 None
2011-10-12 NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses 0 None
2011-10-12 Isis designates ISIS-AATRx candidate in collaboration with GSK 0 None
2011-10-12 Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer 0 None
2011-10-12 Furiex announces publications and presentations about antibacterial drug JNJ-Q2 0 None
2011-10-12 UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs 0 None
2011-10-12 COPAXONE reduces loss of brain volume in patients with RRMS 0 None
2011-10-12 Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes 0 None
2011-10-11 DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study 0 None
2011-10-11 Omeros initiates OMS302 Phase 3 trial in intra-ocular lens replacement surgery 0 None
2011-10-11 DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer 0 None
2011-10-11 Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial 0 None
2011-10-11 ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM 0 4
2011-10-11 Roche's gantenerumab removes amyloid plaques from the brain of patients with AD 0 None
2011-10-11 Takeda, Affymax announce data from multiple studies of peginesatide on anemia 0 None
2011-10-11 Positive results from Biotron's BIT225 Phase 2a trial on HCV 0 None
2011-10-10 Coridon demonstrates 100% protection using DNA HSV-2 vaccine 4 5
2011-10-10 Targacept commences AZD3480 Phase 2b study in Alzheimer’s disease 0 None
2011-10-10 Unither Virology receives NIAID contract for glycobiology antiviral platform 0 None
2011-10-10 Pharmasset adds two treatment arms to PSI-7977 ELECTRON trial on HCV 0 None
2011-10-07 Teriflunomide drug reduces relapse rate of people with MS 0 None
2011-10-07 JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer 0 None
2011-10-04 Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH 0 4
2011-10-04 Clinical study: Higher radiation dose does not improve overall survival for NSCLC 0 None
2011-10-04 DNA primer vaccine enhances immune response to H5N1 avian influenza vaccine 0 None
2011-10-04 Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society 0 None
2011-10-04 Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV 0 None
2011-10-04 AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity 0 None
2011-10-03 Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy 0 None
2011-10-03 EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer 0 None
2011-10-03 Dosing commences in Auxilium's XIAFLEX phase IIIb trial for Dupuytren's contracture 0 None
2011-10-03 GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial 0 None
2011-10-03 Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation 0 None
2011-10-01 The Polyclinic participates in major international HDL clinical research study 0 None
2011-10-01 Planned clinical trial of Adeona's zinc-based therapy for ALS patients to be featured at ALS Summit 0 None
2011-10-01 Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011 0 None
2011-10-01 Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA 0 None
2011-10-01 New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011 0 None
2011-10-01 Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting 0 None
2011-10-01 Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer 0 None
2011-10-01 Baxter seeks European marketing authorization for HyQ to treat PI 0 None
2011-09-30 Roche inaugurates new clinical supply manufacturing facility in Nutley, N.J. 0 None
2011-09-30 Cincinnati Children's to conduct first medication clinical trial for pediatric migraine 0 None
2011-09-30 Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC 0 5
2011-09-30 Small Phase I trial shows HIV vaccine candidate is most powerful to date 0 None
2011-09-30 Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated 0 None
2011-09-29 Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors 0 None
2011-09-29 Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease 0 None
2011-09-29 Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD 0 None
2011-09-29 DSMB authorizes ACT to proceed with next set of patients in stem cell clinical trials 0 5
2011-09-29 Cincinnati Children's to conduct first pediatric migraine medicine clinical trial 0 None
2011-09-29 Almirall submits linaclotide MAA to EMA for treatment of IBS-C 0 None
2011-09-29 VOICE HIV prevention trial to discontinue use of tenofovir tablets 0 None
2011-09-29 Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer 0 None
2011-09-29 SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke 0 4
2011-09-28 Halozyme commences HTI-501 clinical trial for cellulite in women 0 None
2011-09-28 Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV 0 None
2011-09-28 Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease 0 None
2011-09-28 YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis 0 None
2011-09-28 Lovastatin appears to be safe, effective for children with neurofibromatosis type 1 0 None
2011-09-28 BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR 0 2.7
2011-09-28 MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus 0 None
2011-09-27 22nd Century completes enrollment in X-22 Phase II-B smoking cessation study 0 None
2011-09-27 The Nation examines rise in unregulated drug trials in South America 0 None
2011-09-27 HCRI completes enrollment in dual antiplatelet therapy clinical trial 0 None
2011-09-27 Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program 0 None
2011-09-27 Arena, Eisai announce new data from lorcaserin Phase 3 clinical trial program 0 None
2011-09-27 Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting 0 None
2011-09-27 Novartis files marketing authorisation with EMA for NVA237 to treat COPD 0 None
2011-09-27 Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011 0 None
2011-09-27 Zoledronic acid may extend survival in older breast cancer patients 0 None
2011-09-27 Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors 0 None
2011-09-27 Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia 0 None
2011-09-27 Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study 0 None
2011-09-26 Smaller and faster clinical drug trials could improve gains in cancer survival 0 None
2011-09-26 Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting 0 None
2011-09-26 Zoledronic acid may benefit post-menopausal women with breast cancer 0 None
2011-09-26 Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL 1 None
2011-09-26 Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer 0 None
2011-09-26 JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME 0 None
2011-09-26 Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma 0 None
2011-09-26 Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL 0 None
2011-09-26 Ibandronate controls pain in prostate cancer patients with bone metastases 0 None
2011-09-26 InterMune reports new data from Esbriet clinical trial on IPF 0 None
2011-09-26 Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC 0 None
2011-09-26 Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint 0 None
2011-09-26 Combination of Afinitor, exemestane reduces risk of breast cancer progression in women 0 None
2011-09-26 Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials 0 None
2011-09-26 Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer 0 1
2011-09-26 Breast cancer drug combination could stop cancer “in its tracks” 0 None
2011-09-26 Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer 0 None
2011-09-26 Combination of chemo and radiotherapy in breast cancer: Trial 0 None
2011-09-26 Drug combo for breast cancer in post-menopausal women shows promise 0 None
2011-09-26 Zometa bone drug trial in post-menopausal women with breast cancer 0 None
2011-09-26 Embryonic stem cell therapy for incurable Stargardt eye disease 1 4
2011-09-26 The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study 0 None
2011-09-26 First Radium-223 Chloride Phase III study in prostate cancer 0 None
2011-09-26 Combination of everolimus, exemestane holds promise against post-menopausal breast cancer 0 None
2011-09-26 RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome 0 None
2011-09-26 Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women 0 None
2011-09-23 EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection 0 None
2011-09-23 YM BioSciences total revenue decreases to $1.5 million for fiscal 2011 0 None
2011-09-23 Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011 0 None
2011-09-23 Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV 0 None
2011-09-23 E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug 0 None
2011-09-23 Soy protein reduces progression of atherosclerosis in women within 5 years of menopause 0 None
2011-09-23 Researchers to expand malaria vaccine study after initial trial yields encouraging results 0 None
2011-09-23 Researchers compare safety and effectiveness of cryotherapy, salicylic acid for verrucae 0 None
2011-09-23 Levosimendan may effectively improve muscle function in patients with respiratory failure 0 None
2011-09-23 Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011 0 None
2011-09-22 Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma 0 None
2011-09-22 Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC 0 None
2011-09-22 Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis 0 None
2011-09-22 Theraclone initiates TCN-032 Phase 1 trial in influenza A 0 None
2011-09-22 NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF 0 None
2011-09-22 S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women 0 None
2011-09-21 HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients 0 None
2011-09-21 Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD 0 None
2011-09-21 Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA 0 None
2011-09-21 Positive results from Orexo's OX219 clinical study on opioid dependence 0 None
2011-09-20 Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339 0 None
2011-09-20 Gilead’s new 4 in 1 combo HIV pill works 0 None
2011-09-20 U-M Professor to review data from three prominent studies on heart failure 0 None
2011-09-20 Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective 0 None
2011-09-20 New research has potential to alleviate side effects of cancer treatments 0 None
2011-09-20 Tokai raises $23M in Series D3 financing 0 None
2011-09-20 Major donors should consider funding for potential malaria vaccine 0 None
2011-09-20 Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis 0 None
2011-09-20 Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia 0 5
2011-09-20 Infant formulas fortified with LCPUFA are good for developing brains and hearts 0 None
2011-09-20 LA BioMed andrologist leads new male contraceptive Phase I clinical study 0 None
2011-09-20 Scientists pioneer new combination treatment for prostate cancer 0 None
2011-09-20 Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC 0 None
2011-09-19 Preclinical studies shows EmPAC more effective than Taxol 0 None
2011-09-19 Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD 0 None
2011-09-19 Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC 0 None
2011-09-19 Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis 1 5
2011-09-19 Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma 0 None
2011-09-19 Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients 0 None
2011-09-19 Aestus to develop ATx09-002 for treatment of neuropathic pain 0 None
2011-09-19 Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia 0 None
2011-09-19 Karo Bio receives approval to initiate eprotirome phase III study in HeFH 0 None
2011-09-19 NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting 0 None
2011-09-19 Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis 0 None
2011-09-17 Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis 0 None
2011-09-17 Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC 0 None
2011-09-17 Multiple abstracts on QNEXA presented at 47th EASD 0 None
2011-09-17 DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain 0 None
2011-09-17 BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine 0 None
2011-09-16 ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes 0 None
2011-09-16 Linagliptin demonstrates durable reductions in blood glucose for T2D adults 0 None
2011-09-16 Combination of prasugrel plus ASA can treat acute coronary syndrome 0 None
2011-09-16 Anavex announces ANAVEX pre-clinical data on Alzheimer's disease 0 None
2011-09-16 Potential new treatment for fragile X syndrome 0 None
2011-09-16 Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients 0 5
2011-09-16 Experimental malaria vaccine shows positive results among children in small Burkina Faso study 0 None
2011-09-16 Probiotics appear to protect against upper respiratory tract infections 0 None
2011-09-16 Azithromycin gel may treat borreliosis in humans 0 None
2011-09-16 Diclofenac in nano-formulated doses provides effective pain relief 0 None
2011-09-15 CRF announces late breaking trials & first report investigations to be presented at TCT 2011 0 None
2011-09-15 Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society 0 None
2011-09-15 International patient groups anxiously await start of Huntington’s trial 0 5
2011-09-15 KAI enters KAI-4169 development and commercialization agreement with Ono 0 None
2011-09-15 Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment 0 None
2011-09-15 NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma 0 None
2011-09-15 Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes 0 5
2011-09-15 Patients with hepatitis C may benefit from 24 week telaprevir-based regimen 0 None
2011-09-15 Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis 0 None
2011-09-15 First effective blood-stage vaccine against malaria 0 5
2011-09-15 NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C 0 None
2011-09-15 SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease 0 None
2011-09-15 Scientist granted over $138,000 to explore Vitamin C therapy in sepsis 0 5
2011-09-15 Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes 0 None
2011-09-14 Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections 0 None
2011-09-14 Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer 0 None
2011-09-14 Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study 0 None
2011-09-14 New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011 0 None
2011-09-14 Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma 0 None
2011-09-14 Lexicon's LX4211 clinical data presented at EASD annual meeting 0 None
2011-09-14 VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting 0 None
2011-09-14 ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE 0 None
2011-09-14 Acceleron commences ACE-536 Phase 1 clinical trial in anemia 0 None
2011-09-13 New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress 0 None
2011-09-13 Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib 0 None
2011-09-13 Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference 0 None
2011-09-13 ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM 0 None
2011-09-12 Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease 0 4.3
2011-09-12 Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin 0 None
2011-09-12 Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer 0 None
2011-09-12 BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women 0 None
2011-09-12 Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease 0 None
2011-09-12 Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC 0 3
2011-09-12 InteRNA, Silence partner to develop novel microRNA therapeutics for cancer 0 None
2011-09-12 Recruitment complete in Moberg Derma's MOB-015 phase II study for nail fungus 1 None
2011-09-12 Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome 0 5
2011-09-12 UMSOM to receive FDA approval for whole parasite malaria vaccine clinical trials 0 None
2011-09-12 Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer 0 None
2011-09-09 Sangamo's SB-728-T Phase 1 study data on HIV/AIDS to be presented at ICAAC conference 0 4
2011-09-09 Fewer doses of Cervarix vaccine may be as efficacious as standard three-dose regimen 0 None
2011-09-09 Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban 0 None
2011-09-09 Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction 0 None
2011-09-09 Positive results from Sanaria PfSPZ Vaccine initial Phase 1 trial on malaria 0 None
2011-09-08 OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials 0 None
2011-09-08 Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting 0 None
2011-09-08 Better communication needed with at-risk communities for HIV vaccine trials 0 None
2011-09-08 Adding azithromycin to usual daily treatment for COPD reduces acute exacerbations by 27% 0 None
2011-09-07 Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD 0 None
2011-09-07 Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA 0 None
2011-09-07 Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects 0 None
2011-09-07 Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma 0 None
2011-09-07 ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme 0 None
2011-09-07 GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052 0 None
2011-09-07 Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data 0 None
2011-09-06 Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence 0 None
2011-09-06 Enrollment complete in DURECT's POSIDUR Phase III study for post-surgical pain 0 None
2011-09-06 Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints 0 None
2011-09-06 Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease 0 None
2011-09-06 ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL 0 None
2011-09-06 Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1 0 None
2011-09-06 NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease 0 None
2011-09-06 Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma 0 None
2011-09-06 Chondroitin sulfate decreases pain and improves hand function in patients with OA 0 None
2011-09-06 BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer 0 None
2011-09-05 Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks 0 None
2011-09-05 Gilead to amend design of ongoing clinical trials against chronic hepatitis C 0 None
2011-09-03 SWOG selects four cancer researchers for 2011 Young Investigator Training Course 0 None
2011-09-02 Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia 0 None
2011-09-02 New meta-analysis reaffirms safety profile of aspirin for pain relief, fever 0 None
2011-09-02 Valproic acid may increase survival for brain tumor patients 0 None
2011-09-02 New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress 1 None
2011-09-02 UTHealth to study BMS-820836 in Phase II trial for major depressive disorder 0 None
2011-08-31 Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection 0 None
2011-08-31 Eisai announces results of perampanel Phase III study on epilepsy 0 None
2011-08-31 Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes 0 None
2011-08-31 Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study 0 None
2011-08-31 Positive results from Pearl's formoterol fumarate MDI Phase 2b trial on moderate-to-severe COPD 0 None
2011-08-31 Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD 0 None
2011-08-30 Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting 0 None
2011-08-30 Bristol-Myers Squibb selects ICON as preferred provider for early phase clinical development 0 None
2011-08-30 ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma 0 None
2011-08-30 Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress 0 None
2011-08-30 Bristol Meyer Squibb’s new blood thinner drug for stroke prevention 0 None
2011-08-29 Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer 0 None
2011-08-29 Dabigatran etexilate superior to warfarin for stroke prevention in AF patients 0 2
2011-08-29 Everolimus-eluting stent and SES are equally effective for PCI patients 0 None
2011-08-29 Statins protect people against death from respiratory illness, infections 0 None
2011-08-29 ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality 0 None
2011-08-29 Colchicine more effective than placebo for recurrent pericarditis 0 None
2011-08-29 Apixaban superior to warfarin in preventing stroke and systemic embolism 0 None
2011-08-29 Azithromycin can help reduce wheezing, other acute symptoms of COPD 0 None
2011-08-26 BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves 0 None
2011-08-26 Fludrocortisone may help reduce unexplained chronic nausea in children 0 5
2011-08-26 Nasal spray with hot chili pepper ingredient may help people clear up sinus inflammation 0 None
2011-08-26 Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial 0 None
2011-08-25 Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder 0 5
2011-08-25 PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine 0 None
2011-08-25 Azithromycin can effectively reduce acute COPD exacerbations 0 None
2011-08-24 Psoriasis drug and heart attack risk association unclear: Study 0 None
2011-08-24 KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea 0 None
2011-08-24 Kibow renews exclusive worldwide veterinary licensing and marketing agreement 1 None
2011-08-24 United Therapeutics completes treprostinil diethanolamine Phase 3 trial in PAH 0 None
2011-08-24 Avastin increases tumor response rates in breast cancer patients before surgery 0 None
2011-08-24 Celldex announces key in vivo efficacy results of CDX-1135 in Dense Deposit Disease 0 5
2011-08-24 Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma 0 4
2011-08-23 Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia 0 None
2011-08-23 Pearl selects TransPerfect's Trial Interactive eTMF solution for clinical development programs 0 3
2011-08-23 Spinifex secures AU$6.25 million in expanded Series B funding 0 None
2011-08-23 Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer 0 1
2011-08-22 Living Cell Technologies xenoimplants first patients in Argentina trial 0 None
2011-08-20 Researchers turn their attention to Chagas disease as developed countries see rise in infection rates 0 None
2011-08-19 VOA News examines ethics of clinical drug testing in African nations 0 None
2011-08-19 Time-release corticosteroid implant effective in treating uveitis 0 None
2011-08-19 Amgen to present data from several Prolia studies at ASBMR 2011 meeting 0 None
2011-08-19 NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy 0 None
2011-08-19 Minocycline, EDTA may combat catheter-related bacterial infections in dialysis patients 0 3
2011-08-19 FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug 0 None
2011-08-19 Antigen Express provides update on ongoing AE37 Phase 2 trial in breast cancer 0 None
2011-08-18 BTI completes SUGARDOWN human clinical study on blood sugar management 0 None
2011-08-18 New leukemia drug in early clinical testing offers some clues for better treatment 0 None
2011-08-18 FDA approves Mayo Clinic's ovarian and breast cancer vaccines 0 None
2011-08-18 NCRM at Case Western Reserve to host stem cell conference in Cleveland 0 None
2011-08-18 Clinical trials to evaluate and validate infrastructure of P-medicine consortium 0 None
2011-08-18 Endo terminates collaboration and axomadol development program with Grunenthal 0 None
2011-08-18 CEL-SCI receives Chinese patent for Multikine cancer drug 0 None
2011-08-18 Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma 0 None
2011-08-17 Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL 0 4
2011-08-17 Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer 0 None
2011-08-17 GeoVax receives NIH-NIAID grant for HIV/AIDS vaccine program 0 None
2011-08-17 Clinical Trials Partnership Middle East Summit to take place in Dubai 0 None
2011-08-17 Pegloticase can improve clinical outcomes of patients with chronic gout 0 None
2011-08-17 Patient recruitment complete in Kuros' KUR-023 dural sealant European clinical trial 0 None
2011-08-17 FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients 0 None
2011-08-17 Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer 0 None
2011-08-16 Patrys product shows activity in multiple myeloma cancer cells 0 None
2011-08-16 LYSOGENE launches the first gene therapy clinical trials in Sanfilippo disease 0 5
2011-08-16 Zinc lozenges might reduce duration of common cold episodes by 40% 0 None
2011-08-16 Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC 0 None
2011-08-16 AVI BioPharma, MDA to initiate exon-51 Phase 2 trial in Duchenne muscular dystrophy 0 None
2011-08-16 Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia 0 None
2011-08-16 Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome 0 None
2011-08-16 Toclizumab for juvenile rheumatoid arthritis 0 None
2011-08-15 Starpharma starts bacterial vaginosis prevention study of VivaGel 1 None
2011-08-15 Arrythmia drug may work in stroke prevention: Study 0 1
2011-08-11 Pacira second quarter total revenues increase to $3.6 million 0 None
2011-08-11 Aeras, OETC announce initiation of new TB vaccine Phase IIb trial in patients with HIV 0 None
2011-08-11 Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS 0 None
2011-08-11 Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation 0 None
2011-08-10 Israeli OCS approves $1.7M grant to support PROLOR's hGH-CTP program 0 None
2011-08-10 Glenmark commences Revamilast Phase IIb trial in chronic inflammatory disorders 0 None
2011-08-10 NCI, Pharmacyclics sign CRADA to develop PCI-32765 for blood cancers 0 5
2011-08-10 Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis 0 None
2011-08-10 Trastuzumab drug increases risk of heart problems in elderly breast cancer patients 0 None
2011-08-10 Hydros-TA therapy provides next generation of osteoarthritis relief 0 None
2011-08-10 Enobia raises US$40M through private placement 0 None
2011-08-09 Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome 0 None
2011-08-09 Criterium to manage Senesco's SNS01-T Phase Ib/2a multiple myeloma study 0 None
2011-08-09 Lexicon's second quarter revenues decrease 55% to $0.6 million 0 None
2011-08-09 Genentech, Array BioPharma sign oncology agreement for ChK-1 development program 0 None
2011-08-08 22nd Century initiates enrollment in Phase II-B clinical trial of X-22 for smoking cessation 0 None
2011-08-08 Unigene second quarter revenue decreases to $2.5 million 0 None
2011-08-08 Allergan receives positive opinion from Irish Medicines Board for BOTOX 0 None
2011-08-06 VIVUS announces additional data from phase 3 QNEXA studies on obesity 0 None
2011-08-05 Idera second quarter net loss increases to $6.3 million 0 None
2011-08-05 Alexza resubmits AZ-004 NDA for treatment of agitation in schizophrenia patients 0 None
2011-08-05 ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial 0 None
2011-08-05 Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity 0 None
2011-08-05 YM BioSciences reports preclinical results of CYT387 in multiple myeloma 0 None
2011-08-05 FDA grants Orphan Drug Designation to Kamada's AAT product for type 1 diabetes 0 None
2011-08-05 Positive results from Antares Pharma VIBEX MTX clinical study on RA 0 None
2011-08-05 OncoGenex second quarter revenue increases to $1.9 million 0 None
2011-08-04 Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema 0 None
2011-08-04 Palatin confirms initiation of AZD2820 Phase 1 trial in obesity 0 None
2011-08-04 Positive results from hGH-CTP Phase II trial in growth hormone deficient adults 0 None
2011-08-04 NIH-funded study to assess biomarkers in the blood of TBI patients 0 None
2011-08-04 Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial 0 None
2011-08-03 Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia 0 None
2011-08-03 Positive results from combination drug trial for late-stage ovarian cancer 0 None
2011-08-03 Risperidone does not appear to reduce military-related PTSD symptoms 0 None
2011-08-03 Memantine drug could boost cognitive function in people with Down syndrome 0 5
2011-08-03 GSK, NPS enter agreement to evaluate ronacaleret in new indications 0 None
2011-08-02 ARIAD reports $47.8 million net loss for second quarter 2011 0 None
2011-08-02 AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation 1 None
2011-08-02 Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma 0 4
2011-08-02 Insmed receives FDA clinical hold order for ARIKACE phase 3 trials in CF and NTM 0 None
2011-08-02 Can-Fite commences CF101 phase 2/3 trial for treatment of Psoriasis 0 None
2011-08-01 Femta files IND with FDA for FM101 monoclonal antibody against RA 0 None
2011-08-01 Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer 0 None
2011-08-01 Cubist initiates CXA-201 Phase 3 trial in complicated urinary tract infections 0 None
2011-08-01 Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions 0 None
2011-07-30 UH Case Medical Center to commence Phase 1 clinical trial on TMC207 0 None
2011-07-30 UH Rainbow physicians to participate in two new clinical trials with AsthmaNet 0 None
2011-07-29 EGT transfers clinical grade lentiviral vector to MSKCC 0 None
2011-07-29 Positive data from BioMarin's MOR-100 Phase 1/2 extension study on Morquio syndrome 0 None
2011-07-29 Combination drug regimen safe and effective for renal transplant patients 0 None
2011-07-29 Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma 0 3
2011-07-29 Sorrento receives NIAID Phase I STTR grant to develop vaccines against C. difficile infection 0 None
2011-07-29 RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome 0 None
2011-07-28 Curis second quarter net loss increases to $4.9 million 0 None
2011-07-28 Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress 0 None
2011-07-27 Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer 0 None
2011-07-27 Amphetamines can control ADHD symptoms in adults 0 4
2011-07-27 New preclinical data from Baxter's BAX 499 hemophilia study presented at ISTH 0 None
2011-07-27 Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD 0 None
2011-07-27 Ceridia completes CER006 Phase 1 Proof-of-Concept study in humans 0 None
2011-07-27 NSU, Immunotec collaborate to determine effects of Immunocal on children with ASD 0 3
2011-07-27 Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia 0 None
2011-07-26 Anavex presents data on neuroprotective evidence for lead compound for Alzheimer’s 0 None
2011-07-26 Selexis, CSL enter commercial license agreement for therapeutic antibody 0 None
2011-07-26 Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A 0 None
2011-07-26 Zinc lozenges might treat natural common cold infections 0 None
2011-07-26 Debiopharm, INC Research partner for clinical development programmes 0 None
2011-07-26 PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials 0 None
2011-07-26 Advaxis submits protocol revision for ADXS-HPV CIN Phase II study 0 None
2011-07-25 Adaptimmune announces opening of pilot clinical trial in synovial sarcoma 0 None
2011-07-25 Promising drug for Duchenne muscular dystrophy 1 5
2011-07-25 Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma 0 None
2011-07-25 Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy 0 None
2011-07-25 Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma 0 None
2011-07-25 Bionovo completes 13 weeks repeat dose animal toxicology studies for Menerba 0 None
2011-07-25 BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain 0 None
2011-07-25 Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine 0 None
2011-07-25 R-Tech Ueno announces protocol amendment of RK-023 Phase I trial for eyelash hypotrichosis 0 None
2011-07-22 22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial 0 None
2011-07-22 Enrollment begins in Repligen's RG1068 pilot study to improve detection, staging of pancreatic cancer 0 None
2011-07-22 UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV 0 None
2011-07-22 Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer 0 None
2011-07-22 Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma 0 None
2011-07-21 BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation 0 None
2011-07-21 Isis commences ISIS-PTP1BRx Phase 1 study in type 2 diabetes 0 None
2011-07-21 PAREXEL completes 100th Asian ethnobridging study 0 None
2011-07-21 Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results 0 None
2011-07-21 Children and adults with social withdrawal due to Fragile X may benefit from STX209 0 None
2011-07-21 Clinical study of anti-HIV antibody made from genetically modified tobacco plants 0 None
2011-07-21 Boosted REYATAZ shows durable viral suppression in women with HIV 0 None
2011-07-21 Bristol-Myers Squibb announces results of BMS-708163 Phase II study on Alzheimer's 0 None
2011-07-21 Promising results from phase I study of Genentech's GDC-0941 for advanced breast cancer 0 None
2011-07-20 Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV 0 None
2011-07-20 Three-drug regimen more effective for treating H. pylori infection 0 None
2011-07-20 NCCN experts recommend bevacizumab for treating metastatic breast cancer 0 None
2011-07-20 Chemotherapy combined with anti-cancer agent shows promise for treatment of aggressive breast cancers 0 None
2011-07-20 Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee 0 None
2011-07-20 Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference 0 None
2011-07-20 Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma 0 None
2011-07-20 CEL-SCI expands licensing agreement with Teva for Multikine cancer drug 0 None
2011-07-19 Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011 0 None
2011-07-19 Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy 0 None
2011-07-18 Upsher-Smith initiates USL261 ARTEMIS1 Phase III study for seizure clusters in epilepsy patients 0 None
2011-07-18 ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients 0 None
2011-07-18 Study: IL-2 monotherapy not effective as maintenance therapy for acute myeloid leukemia 0 None
2011-07-18 Positive results from levomilnacipran Phase III study for major depressive disorder 0 3
2011-07-18 SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load 0 5
2011-07-15 Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer 0 None
2011-07-15 CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint 0 None
2011-07-15 BioMarin commences BMN 673 Phase 1 trial in hematological malignancies 0 None
2011-07-14 Michael J. Fox Foundation awards Impax $400,000 grant for research of IPX066 for Parkinson’s disease 0 None
2011-07-14 Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza 0 None
2011-07-14 Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review 0 None
2011-07-14 PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate 0 None
2011-07-14 DARA's DB959 shows promise against type 2 diabetes 0 None
2011-07-14 Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT 0 None
2011-07-14 ASLAN, Array sign license agreement to develop ARRY-543 for solid tumors 0 None
2011-07-14 Fish oil consumption helps reduce inflammation, anxiety in healthy young people 0 None
2011-07-13 Cerulean initiates CRLX101 Phase 2 trial in non-small cell lung cancer 0 None
2011-07-13 UIC to begin STX209 clinical trial for treatment of autism spectrum disorders 0 None
2011-07-13 Blood cancer drug trial results questioned by FDA 0 1
2011-07-13 Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis 0 None
2011-07-13 Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension 0 None
2011-07-12 Enrollment complete in Advaxis ADXS-HPV Phase II CIN study 0 None
2011-07-11 Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury 0 None
2011-07-11 Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia 0 None
2011-07-11 FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression 0 None
2011-07-11 Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line 0 None
2011-07-11 Combination therapy shows promise against HER2-positive metastatic breast cancer 0 None
2011-07-11 Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis 0 None
2011-07-11 Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes 0 None
2011-07-08 Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency 0 None
2011-07-08 Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea 0 None
2011-07-08 First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma 0 None
2011-07-08 Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck 0 None
2011-07-08 Collaborative research discovers broadly acting antibody against influenza viruses 0 None
2011-07-08 Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint 0 None
2011-07-08 Exenatide tQT clinical trial meets pre-specified primary endpoint 0 None
2011-07-08 Enrollment commences in InterMune's Esbriet Phase 3 study for IPF 0 None
2011-07-07 Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux 0 None
2011-07-07 Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference 0 None
2011-07-06 High-dose aspirin could help prevent cardiovascular disease in diabetic patients 0 None
2011-07-06 Older people, women and minorities enrolled less frequently in lung cancer drug trials 0 None
2011-07-06 Former smokers with lung cancer can benefit from celecoxib treatment 0 None
2011-07-05 Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy 0 None
2011-07-05 Erlotinib phase III study results on lung cancer presented at IASLC conference 0 None
2011-07-01 FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer 0 None
2011-07-01 Tranexamic acid effective for patients with head injury 0 None
2011-07-01 Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO 0 None
2011-06-30 Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia 1 None
2011-06-30 Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture 0 5
2011-06-30 PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint 0 None
2011-06-30 Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial 0 None
2011-06-30 Novartis reports NVA237 Phase III trial results against COPD 0 None
2011-06-30 Conference examines lagging ethical guidelines in face of expanding clinical trials in developing countries 0 None
2011-06-30 Provectus presents additional data on PV-10 at two separate melanoma conferences 0 None
2011-06-29 Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing 0 None
2011-06-29 Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis 0 None
2011-06-29 Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET 0 None
2011-06-29 USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy 0 None
2011-06-29 Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness 0 None
2011-06-29 Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet 0 None
2011-06-29 Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema 0 None
2011-06-29 Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients 0 None
2011-06-29 FDA clears Nuvo's IND for Lidocaine Spray formulation 0 None
2011-06-28 Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients 0 None
2011-06-28 FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma 0 None
2011-06-28 Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction 0 2
2011-06-28 BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia 0 None
2011-06-28 Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011 0 None
2011-06-28 Ticagrelor drug with low-dose aspirin effective against acute coronary syndrome 0 None
2011-06-28 TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011 0 None
2011-06-28 Yale University: Gabapentin clinical study on epilepsy may have been a 'seeding trial' 0 None
2011-06-28 ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint 0 None
2011-06-28 Researchers, policy experts to examine issue of declining enrollment in clinical trials 0 None
2011-06-28 Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website 0 None
2011-06-28 Microbix renegotiates key terms of Hunan influenza vaccine joint venture 0 None
2011-06-28 Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure 0 None
2011-06-28 Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis 0 None
2011-06-27 New and effective diabetes drug seeking approval 0 5
2011-06-27 Nile completes dosing in Part B of cenderitide Phase I study for ADHF 0 None
2011-06-27 Cardium to purchase Transdel's business assets 0 None
2011-06-27 Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease 0 None
2011-06-27 Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial 6 5
2011-06-27 Genentech, FORMA enter structurally innovative agreement for small molecule cancer program 0 None
2011-06-27 EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease 0 None
2011-06-27 FDA responds to EpiCept Ceplene SPA 0 None
2011-06-27 Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD 0 None
2011-06-27 Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer 0 None
2011-06-27 Biota reports preliminary data from CS-8958 Phase III trial against influenza 0 None
2011-06-27 Positive results from Stealth's Bendavia Phase I renal impairment study 0 None
2011-06-27 Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011 0 None
2011-06-27 New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011 0 3.8
2011-06-27 Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes 0 5
2011-06-27 New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011 0 3.5
2011-06-27 Promising results from MGH's BCG Phase I trial on type I diabetes 1 None
2011-06-27 Diabetic patients can benefit from basal insulin analogs 0 None
2011-06-27 New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011 0 None
2011-06-24 PCIB reports main results of Amphinex Phase I/II study against multiple cancers 0 None
2011-06-24 InVasc commences INV-144 Phase IIa trial in chronic kidney disease 0 None
2011-06-24 Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's 0 None
2011-06-24 Nature News examines controversy surrounding Indian HPV vaccine trial 0 None
2011-06-24 Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma 0 None
2011-06-24 Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011 0 None
2011-06-24 Oxytocin hormone holds promise for children with Prader-Willi syndrome 1 None
2011-06-24 Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS 0 1
2011-06-24 GeoVax opens third clinical trial site for testing HIV/AIDS vaccine 0 None
2011-06-24 Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer 0 None
2011-06-23 Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals 0 None
2011-06-23 FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency 0 None
2011-06-23 MAP to present LEVADEX data on migraine at 15th Congress of IHC 0 None
2011-06-23 Positive results from Neurelis NRL-1 Phase I pharmacokinetic study on acute repetitive seizures 0 None
2011-06-23 Monash researchers receive MMV Project of the Year award for new anti-malarial drug candidate 0 None
2011-06-23 Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes 0 None
2011-06-23 Telaprevir drug shows promise in curing hepatitis C infection 0 None
2011-06-22 Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection 0 None
2011-06-22 Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder 0 None
2011-06-22 Naurex commences GLYX-13 Phase II trial in treatment-resistant depression 0 None
2011-06-22 Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011 0 None
2011-06-22 Endotis commences EP217609 Phase IIa study in patients undergoing open-heart surgery 0 None
2011-06-22 Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD 0 None
2011-06-22 Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis 0 None
2011-06-22 Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C 0 None
2011-06-22 Pycnogenol, CoQ10 combination boost heart function 0 4
2011-06-22 Results of African malaria vaccine trial expected later this year 0 None
2011-06-22 CEL-SCI announces results from Multikine Phase II trial on head and neck cancer 0 None
2011-06-22 Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint 0 1
2011-06-21 Seaside Therapeutics commences STX209 Phase 2b study in autism spectrum disorders 0 None
2011-06-21 DIA recognizes CAPRISA team for outstanding achievement in HIV prevention 0 None
2011-06-21 Positive results from LCP-Tacro Phase III trial in stable kidney transplant recipients 0 None
2011-06-21 Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011 0 5
2011-06-21 Halozyme to present three data on Ultrafast Insulin programs at ADA 2011 0 None
2011-06-21 Lilly, Boehringer Ingelheim to present new data from diabetes portfolio at ADA scientific sessions 0 None
2011-06-21 New clinical trial to evaluate safety of tenofovir gel in breastfeeding, pregnant women 0 None
2011-06-21 Amylin to present data on investigational diabetes drug candidates at ADA annual meeting 0 None
2011-06-20 Initiation of ALD518/BMS-945429 Phase 2b clinical trial in RA triggers milestone payment to Alder 0 None
2011-06-20 Spectrum announces various clinical studies on ZEVALIN at ICML 2011 0 None
2011-06-20 Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity 0 5
2011-06-20 GTx commences Capesaris Phase IIb trial in advanced prostate cancer 0 None
2011-06-20 Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome 0 None
2011-06-20 Positive results from vismodegib Phase II study on advanced basal cell carcinoma 0 None
2011-06-20 Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011 0 None
2011-06-18 Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas 0 None
2011-06-17 Positive data from Ischemix CMX-2043 Phase 2a trial for peri-operative cardiac ischemia-reperfusion injury 0 None
2011-06-17 Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital 0 None
2011-06-17 Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL 0 None
2011-06-17 VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints 0 None
2011-06-17 Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma 0 None
2011-06-17 REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference 0 None
2011-06-17 Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD 0 None
2011-06-17 CTI announces positive results from Phase I-II pixantrone combination study against INHL 0 None
2011-06-17 Experimental vaccine shows promise for patients with newly diagnosed brain tumors 0 None
2011-06-17 Positive results from etanercept pilot study against dermatomyositis 0 None
2011-06-17 BioClinica releases new Trident IWR solution 0 None
2011-06-16 New Australian drug shows positive response in patients with multiple myeloma blood cancer 3 2.4
2011-06-16 Adaptimmune melanoma trial opening 0 None
2011-06-16 Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis 0 None
2011-06-16 Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia 0 None
2011-06-16 Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections 0 None
2011-06-16 Large trial of tenofovir gel for women set to begin in South Africa 0 None
2011-06-16 Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza 0 None
2011-06-16 Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists 0 None
2011-06-16 Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011 0 None
2011-06-16 Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings 0 None
2011-06-16 Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences 0 None
2011-06-16 Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease 0 None
2011-06-15 Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression 0 None
2011-06-15 Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID 0 None
2011-06-15 Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer 0 None
2011-06-15 immatics initiates IMA901 Phase III trial in renal cell carcinoma 0 None
2011-06-15 Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011 0 None
2011-06-15 Sangart commences MP4OX Phase 2b study in acute traumatic injury 0 None
2011-06-15 Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen 0 None
2011-06-15 Positive results from Neurelis NRL-01 Phase 1 trial against epilepsy 0 None
2011-06-14 CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury 0 None
2011-06-14 The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial 0 None
2011-06-14 TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes 0 None
2011-06-14 New findings from Deplin clinical trial on major depressive disorder presented at NCDEU 1 5
2011-06-14 Orexo completes first OX27 pharmacokinetic trial against breakthrough pain in cancer 0 None
2011-06-14 GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE 0 None
2011-06-14 FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer 0 None
2011-06-14 Cinryze data on hereditary angioedema presented at EAACI 2011 0 None
2011-06-14 Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML 0 None
2011-06-13 Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia 0 None
2011-06-13 Study reveals positive impact of Soliris on long-term outcomes in PNH patients 1 5
2011-06-13 CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary 0 None
2011-06-13 Trimeris, Synageva enter definitive merger agreement 0 None
2011-06-13 Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma 0 None
2011-06-13 Circassia announces ToleroMune vaccine phase II trial results against cat allergy 0 None
2011-06-13 Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials 0 None
2011-06-13 Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis 0 3
2011-06-13 Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA 0 None
2011-06-13 Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011 0 None
2011-06-10 Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia 0 5
2011-06-10 Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function 0 4
2011-06-10 Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011 0 None
2011-06-10 FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma 0 None
2011-06-10 Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting 0 None
2011-06-09 Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease 0 None
2011-06-09 Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis 0 5
2011-06-09 ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme 0 None
2011-06-09 Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis 0 None
2011-06-09 TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs 0 None
2011-06-09 Patient enrollment complete in cilengitide Phase III study against glioblastoma 0 3
2011-06-09 Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease 0 None
2011-06-09 FDA accepts Adamis IND for APC-100 to treat prostate cancer 0 None
2011-06-08 Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO 0 None
2011-06-08 Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection 0 None
2011-06-08 New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA 0 None
2011-06-08 Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C 0 None
2011-06-08 Millennium reports results from two VELCADE based combination studies against multiple myeloma 0 None
2011-06-08 Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates 0 None
2011-06-08 Vaccine candidate produces immune response to antigen in all strains of influenza A 0 None
2011-06-08 Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis 0 None
2011-06-08 Cabozantinib shows early promise in treatment of prostate cancer spread to the bone 0 None
2011-06-08 MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension 0 None
2011-06-08 MicroDose completes atropine inhaler Phase I study on nerve agent poisoning 0 None
2011-06-08 SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189 0 None
2011-06-08 Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne 0 None
2011-06-08 Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS 0 None
2011-06-07 Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011 0 None
2011-06-07 LLS announces four new Academic Concierge partnerships for cancer drug development 0 None
2011-06-07 Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences 1 None
2011-06-07 NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011 0 None
2011-06-07 ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011 0 None
2011-06-07 AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis 0 2
2011-06-07 Unique clinical trial addresses important questions about treating AIDS-related cancers 0 None
2011-06-07 Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011 0 4
2011-06-07 Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting 0 None
2011-06-07 FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold 0 None
2011-06-07 Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study 0 None
2011-06-07 Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma 0 None
2011-06-07 Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer 0 None
2011-06-07 Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint 0 None
2011-06-07 SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music 0 None
2011-06-07 Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011 0 None
2011-06-07 Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011 0 None
2011-06-07 VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011 0 None
2011-06-07 Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria 0 None
2011-06-07 Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC 0 None
2011-06-07 Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011 0 None
2011-06-07 Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011 0 None
2011-06-07 Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint 0 None
2011-06-07 Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011 0 4
2011-06-07 Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO 0 None
2011-06-06 Trifunctional antibody Catumaxomab triggers vaccination effect against cancer 0 None
2011-06-06 Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year 0 None
2011-06-06 Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011 0 None
2011-06-06 Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer 0 None
2011-06-06 Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011 0 None
2011-06-06 Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma 0 None
2011-06-06 Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis 0 None
2011-06-06 Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation 0 None
2011-06-06 Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011 0 None
2011-06-06 Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011 0 None
2011-06-06 Chiasma presents Octreolin pharmacology data from clinical studies at International Pituitary Congress 0 None
2011-06-06 GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC 0 None
2011-06-06 United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension 0 None
2011-06-06 NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011 0 None
2011-06-06 Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC 0 None
2011-06-06 Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO 0 5
2011-06-06 Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO 0 None
2011-06-06 New targeted therapy may halt tumor growth in men with advanced prostate cancer 0 None
2011-06-06 Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO 0 5
2011-06-06 Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011 0 None
2011-06-06 New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO 0 1
2011-06-06 Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint 0 None
2011-06-06 ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011 0 None
2011-06-06 Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011 0 None
2011-06-06 Women with breast cancer do not benefit from flaxseed 0 None
2011-06-06 Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint 0 None
2011-06-06 Ipsen decides to assess development of Irosustat in combination with hormonal therapies 0 None
2011-06-06 Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer 0 4
2011-06-06 ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011 0 None
2011-06-06 Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011 0 None
2011-06-06 Exemestane reduces risk of breast cancer in high-risk, postmenopausal women 0 None
2011-06-06 Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma 0 None
2011-06-05 Ross River Fever vaccine trials begin 1 None
2011-06-04 Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer 0 None
2011-06-04 Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011 0 None
2011-06-04 Study links loss of PTEN gene with patient's response to melanoma therapy 0 None
2011-06-04 Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's 0 None
2011-06-04 U of A researchers try to combat heart disease in cancer patients 0 None
2011-06-04 Bionovo's Menerba Phase 2 trial data to be presented at Annual World Congress on Menopause 0 5
2011-06-04 Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011 0 None
2011-06-04 Researcher to evaluate new approach for treatment of triple-negative breast cancer 0 None
2011-06-04 Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC 0 None
2011-06-04 Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma 0 None
2011-06-04 Nano-formulated indomethacin at lower dose effective in treating pain 0 5
2011-06-04 EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011 0 None
2011-06-04 Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011 0 None
2011-06-04 YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis 0 None
2011-06-04 Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma 0 None
2011-06-04 Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer 0 None
2011-06-04 Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma 0 None
2011-06-03 Cancer vaccine shows improved response rate in patients 0 None
2011-06-03 ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011 0 None
2011-06-03 ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011 0 None
2011-06-03 APC8015F investigational vaccine improves survival of prostate cancer patients 0 None
2011-06-03 Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men 0 5
2011-06-03 Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis 0 None
2011-06-03 Angiotensin receptor blockers do not increase risk of cancer: FDA 0 None
2011-06-03 Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial 0 None
2011-06-03 VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers 0 None
2011-06-02 Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome 0 None
2011-06-02 Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011 0 None
2011-06-02 Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial 0 None
2011-06-02 AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011 0 None
2011-06-02 Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting 0 None
2011-06-02 Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab 0 None
2011-06-02 Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011 0 5
2011-06-02 Anadys receives U.S. patent for setrobuvir to treat chronic hepatitis C 0 None
2011-06-02 Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia 0 None
2011-06-02 Fero Industries completes Sucanon human clinical trials on Type-2 diabetes 0 None
2011-06-01 Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma 0 None
2011-06-01 Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011 0 5
2011-06-01 Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011 0 None
2011-06-01 Diamyd European Phase III study in diabetes does not meet primary endpoint 0 None
2011-06-01 CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study 0 None
2011-06-01 Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease 0 None
2011-06-01 Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis 0 None
2011-05-31 Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study 0 None
2011-05-31 YM announces updates on nimotuzumab clinical development program 0 None
2011-05-30 Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer 0 None
2011-05-30 New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting 0 None
2011-05-27 Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values 0 None
2011-05-27 Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA 0 None
2011-05-27 NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol 1 4
2011-05-27 4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011 0 None
2011-05-27 ARCA plans to expand development program for Gencaro in atrial fibrillation 0 None
2011-05-27 Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis 0 None
2011-05-27 Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice 0 5
2011-05-27 Tacrolimus prevents breast cancer growth in pre-clinical studies 0 None
2011-05-27 Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress 0 None
2011-05-27 Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer 0 None
2011-05-26 Gout drug success for Novartis 0 None
2011-05-26 Specific influenza immunization strategies for RA patients may be required for future flu pandemics 0 None
2011-05-26 iBioLaunch Platform successfully expresses hookworm-derived molecule for potential vaccine 0 None
2011-05-26 Pharmasset, Bristol-Myers Squibb initiate PSI-7977 plus BMS-790052 combination Phase 2a trial in HCV 0 None
2011-05-26 BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011 0 None
2011-05-26 ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011 0 None
2011-05-26 Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome 0 None
2011-05-26 Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011 0 None
2011-05-26 NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial 0 None
2011-05-26 Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections 0 None
2011-05-26 Tofacitinib safe and effective for patients with rheumatoid arthritis 0 None
2011-05-26 Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout 0 None
2011-05-26 NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer 0 None
2011-05-25 PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings 0 None
2011-05-25 Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks 0 None
2011-05-25 Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors 0 None
2011-05-25 Avanafil phase 3 trial in ED following radical prostatectomy meets primary endpoints 0 None
2011-05-25 New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology 0 None
2011-05-25 Oral and injected steroids appear to be equally effective for sudden hearing loss 0 None
2011-05-25 CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209 0 None
2011-05-25 Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011 0 None
2011-05-25 Conference reviews recent evidence that links aspirin use with reduced risk of several cancers 0 None
2011-05-25 New clinical research study to compare two medications for bipolar disorder 1 None
2011-05-25 Positive interim results from new bladder cancer therapy trial 0 None
2011-05-25 ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011 0 None
2011-05-24 Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis 0 None
2011-05-24 3M, Radius collaborate to develop BA058 for treatment of osteoporosis 0 None
2011-05-24 Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011 0 5
2011-05-24 Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS 0 None
2011-05-24 VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011 0 None
2011-05-24 Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia 0 None
2011-05-24 Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma 0 None
2011-05-23 Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting 0 None
2011-05-23 Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011 0 None
2011-05-23 Micromet's blinatumomab data to be presented at two upcoming medical meetings 0 None
2011-05-23 Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting 0 None
2011-05-23 New RHUCIN study data in acute HAE attacks presented at 7th C1 Inhibitor Deficiency Workshop 0 None
2011-05-23 Phytoceuticals to present promising clinical data on 1 PRIMARY WOUND DRESSING at EWMA 2011 0 None
2011-05-23 New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting 1 5
2011-05-23 Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure 0 None
2011-05-21 Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination 0 None
2011-05-21 Phase 3 open-label study of RELISTOR presented at American Pain Society meeting 0 None
2011-05-21 Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting 0 None
2011-05-21 Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011 0 None
2011-05-20 Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer 0 None
2011-05-20 Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C 0 None
2011-05-20 RTOG reports on largest trial for newly diagnosed glioblastoma 0 None
2011-05-20 AMT presents long-term efficacy study of Glybera in treatment of lipoprotein lipase deficiency 0 5
2011-05-20 Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011 0 None
2011-05-20 VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT 0 None
2011-05-20 Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO 0 None
2011-05-20 Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma 0 None
2011-05-20 ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection 0 None
2011-05-20 CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia 0 5
2011-05-19 Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer 0 None
2011-05-19 Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence 0 None
2011-05-19 Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout 1 None
2011-05-19 PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies 0 None
2011-05-19 RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011 0 None
2011-05-19 Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy 0 None
2011-05-19 Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study 0 None
2011-05-19 Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs 0 None
2011-05-19 AstraZeneca announces encouraging results from olaparib phase II study in serous ovarian cancer 0 None
2011-05-19 TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis 0 None
2011-05-19 YM BioSciences announces updated interim results from CYT387 Phase I/II trial in myelofibrosis 0 None
2011-05-19 Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting 0 None
2011-05-19 Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints 0 None
2011-05-19 Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting 0 None
2011-05-19 Mpex, Synteract partner for cystic fibrosis fundraising event 0 None
2011-05-19 Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer 0 None
2011-05-18 Pharma Two B plans to initiate P2B001 Phase II study in Parkinson's disease 0 None
2011-05-18 New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting 0 None
2011-05-18 New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference 0 None
2011-05-18 JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia 0 5
2011-05-18 Bayer HealthCare to present results on investigational oncology compounds at ASCO annual meeting 0 None
2011-05-18 CITN selects Cytheris' CYT107 for initial clinical trials at network institutions 0 None
2011-05-18 Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer 0 None
2011-05-18 Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints 0 5
2011-05-18 Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting 0 None
2011-05-18 Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder 0 None
2011-05-18 CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada 0 None
2011-05-18 Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis 0 None
2011-05-17 Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma 0 None
2011-05-17 Thrombolytic therapy linked to poor survival in pulmonary embolism patients with normal blood pressure 0 None
2011-05-17 Sanofi hopes to launch dengue vaccine in 2014 0 4
2011-05-17 SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011 0 None
2011-05-17 Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study 0 None
2011-05-16 Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference 0 None
2011-05-16 Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients 0 3
2011-05-16 Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting 0 None
2011-05-16 Synexus completes CT327 phase II psoriasis trial for Creabilis 0 3
2011-05-16 New lenalidomide phase III study data presented at 13th International Myeloma Workshop 0 None
2011-05-16 Early HIV treatment can reduce transmission risk by 96%, preliminary study results show 0 None
2011-05-16 Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme 0 None
2011-05-16 VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD 1 3
2011-05-16 Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder 0 None
2011-05-16 The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis 0 None
2011-05-13 CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland 0 None
2011-05-13 ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer 0 None
2011-05-13 Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting 0 None
2011-05-13 Early antiretroviral treatment can halt HIV spread in couples 0 None
2011-05-12 Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment 0 None
2011-05-12 New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections 0 None
2011-05-12 CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections 0 None
2011-05-12 Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis 0 None
2011-05-12 Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting 0 None
2011-05-12 Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting 0 None
2011-05-12 GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores 0 None
2011-05-11 Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment 0 None
2011-05-11 ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer 0 None
2011-05-11 Symphogen to present second-generation Sympress platform at ESACT conference 0 None
2011-05-11 TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome 0 None
2011-05-11 Impax Pharmaceuticals initiates IPX159 Phase I study in Restless Legs Syndrome 0 None
2011-05-11 GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011 0 None
2011-05-11 Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference 0 None
2011-05-11 Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA 0 None
2011-05-11 Inovio first quarter total revenue increases to $3.1 million for 2011 0 None
2011-05-11 Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference 0 None
2011-05-11 New drug targets bile acid to provide relief from constipation 0 None
2011-05-11 New Crohn’s disease therapy on its way 1 None
2011-05-10 Dalbavancin surveillance antibiotic results for Gram-positive pathogens presented at ECCMID meeting 0 None
2011-05-10 Independent investigator begins pump trial of Biodel's two ultra-rapid human insulin formulations 0 None
2011-05-10 Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID 0 None
2011-05-10 biocrea and Pfizer jointly presented details on novel PDE10 inhibitors 0 None
2011-05-10 Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST 0 None
2011-05-10 Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients 0 None
2011-05-10 Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC 0 None
2011-05-10 MGH, Duke University and Angion Biomedica partner to develop novel therapeutics for ischemic stroke 0 None
2011-05-10 OncoGenex first quarter revenue decreases to $1.2 million 0 None
2011-05-10 Kowa presents three K-115 study results against glaucoma at ARVO 2011 0 None
2011-05-10 Nexvax2- coeliac disease vaccine shows promising results in Phase I clinical trial 0 5
2011-05-10 Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting 0 None
2011-05-10 Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011 0 None
2011-05-09 Uganda: First vaccination for GMZ2 malaria vaccine trial 0 None
2011-05-09 New GARDASIL data against Human Papillomavirus presented at EUROGIN conference 0 3
2011-05-09 GTx reports net loss of $2.6 million for first quarter 2011 0 None
2011-05-09 EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia 0 None
2011-05-09 Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer 0 None
2011-05-09 Diamyd Medical announces European Phase III study results in type 1 diabetes 0 None
2011-05-07 Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting 0 None
2011-05-07 Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting 0 None
2011-05-06 ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme 0 None
2011-05-06 Millennium presents three studies in relapsed multiple myeloma at IMW meeting 0 None
2011-05-06 Pacira to present EXPAREL data in postsurgical pain at two medical meetings 0 None
2011-05-06 Omeros' PDE7 program expands addiction franchise 0 None
2011-05-06 MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment 0 None
2011-05-06 Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress 0 None
2011-05-05 Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011 0 None
2011-05-05 Over 1000 patients enrolled in world's largest ever pancreatic cancer vaccine trial 0 None
2011-05-05 Clinical study: Celecoxib drug may treat breast cancer 0 None
2011-05-05 CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer 0 None
2011-05-05 Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease 0 None
2011-05-04 FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients 0 None
2011-05-04 PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting 0 None
2011-05-04 SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial 0 None
2011-05-04 pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011 0 None
2011-05-04 Top-line results from Lymphoseek NEO3-09 Phase 3 study in breast cancer, melanoma 0 None
2011-05-03 Nile Therapeutics initiates cenderitide Phase I trial in heart failure 0 None
2011-05-03 Santarus' budesonide MMX Phase III data in ulcerative colitis to be presented at DDW 2011 0 None
2011-05-03 Affinium announces AFN-1252 Phase I study results in staphylococcal infections 0 None
2011-05-03 Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia 0 None
2011-05-03 Merck's Phase III study shows efficacy results of tafluprost to treat ocular hypertension 0 None
2011-05-03 Diabetes cell implant company approved for Argentina clinical trial 0 None
2011-05-02 Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration 0 None
2011-04-30 Pearl's PT003 Phase 2b study results in COPD to be presented at ATS meeting 0 None
2011-04-30 CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada 0 None
2011-04-29 Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients 0 None
2011-04-29 MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals 0 None
2011-04-29 Top-line results from Pfizer's tofacitinib Phase 3 studies in RA 0 None
2011-04-28 CEL-SCI initiates Multikine Phase III trial in head and neck cancer 1 None
2011-04-28 FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer 0 None
2011-04-28 Curis reports first quarter net loss of $6.8 million 0 None
2011-04-28 Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease 0 None
2011-04-28 Positive results from Shire's Vyvanse clinical trial in schizophrenia 0 3
2011-04-28 Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million 0 None
2011-04-28 Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME 0 None
2011-04-28 The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence 0 None
2011-04-28 Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women 0 None
2011-04-28 FDA Advisory Committee recommends approval of Merck's VICTRELIS for chronic HCV genotype 1 infection 0 None
2011-04-27 CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC 0 None
2011-04-27 Children, adolescents with liver disease may not benefit from vitamin E or metformin 0 None
2011-04-27 BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis 0 None
2011-04-27 Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV 0 2
2011-04-27 Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC 0 None
2011-04-27 IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax 0 None
2011-04-27 Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT 0 None
2011-04-26 FDA supports new Hepatitis C drug from Vertex Pharmaceuticals 0 None
2011-04-26 Diabetes and prediabetes are on the rise: New medication in research trials 0 None
2011-04-26 Millennium submits two VELCADE sNDAs to FDA 0 None
2011-04-26 USPTO grants Cortex patent for CX1739 AMPAKINE molecule 0 None
2011-04-26 Pharmacyclics receives Servier's $7 million milestone payment for HDAC inhibitor 0 None
2011-04-26 Dactinomycin more effective for low-risk gestational tumor treatment 0 None
2011-04-26 HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease 0 None
2011-04-26 BMY to present belatacept Phase III new data at American Transplant Congress 0 None
2011-04-25 A.P. Pharma targets resubmission of APF530 NDA in 2012 0 None
2011-04-25 Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis 0 None
2011-04-25 XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis 0 None
2011-04-25 Individuals on SSRIs still exhibit depressive symptoms 0 None
2011-04-25 Pfizer comments on abstract concerning ORAL Sync tofacitinib Phase 3 study in RA 0 None
2011-04-25 Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings 0 None
2011-04-22 Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients 0 None
2011-04-22 Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer 0 None
2011-04-22 BioCryst's BCX4208 study results in gout to be presented at EULAR meeting 0 None
2011-04-22 Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting 0 None
2011-04-22 Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder 0 None
2011-04-22 Convergence initiates CNV2197944 Phase I study in chronic pain 0 None
2011-04-22 JASN publishes positive results from pirfenidone study in diabetic nephropathy 0 None
2011-04-21 Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine 0 None
2011-04-21 Merrimack initiates dosing in MM-111 combination Phase 1 study in advanced HER2 positive patients 0 None
2011-04-21 Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer 0 None
2011-04-21 Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications 0 3
2011-04-21 Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability 0 None
2011-04-21 New trial in UK to test whether statins could be used to treat pre-eclampsia 0 None
2011-04-21 Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis 0 None
2011-04-20 Anavex: First-in-human dosing cmmenced in ANAVEX 2-73 clinical trial for Alzheimer’s 0 None
2011-04-20 Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637 0 None
2011-04-20 Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011 0 None
2011-04-20 Aduro raises $19.25 million through Series B equity financing 0 None
2011-04-20 Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells 0 None
2011-04-20 Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer 0 None
2011-04-20 Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic 0 None
2011-04-20 Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections 0 None
2011-04-20 Advancell initiates ATH008 phase IIb study for hand-foot syndrome 0 None
2011-04-20 Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint 0 None
2011-04-20 Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal 0 None
2011-04-20 Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial 0 None
2011-04-19 African AIDS drug trial stopped prematurely 0 None
2011-04-19 NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction 0 None
2011-04-19 Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis 0 None
2011-04-19 Circassia closes $98 million fundraising for lead allergy programmes 0 None
2011-04-19 Novartis NVA23 Phase III trial in COPD achieves primary end point 0 None
2011-04-19 Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL 0 None
2011-04-18 Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia 0 None
2011-04-18 Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV 0 None
2011-04-18 Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI 0 None
2011-04-18 Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides 0 None
2011-04-16 GRAVITAS study shows no benefit of double-dose compared with standard-dose clopidogrel 0 None
2011-04-16 Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting 0 None
2011-04-16 Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting 0 None
2011-04-16 New results from largest multicenter clinical trial for heart transplant patients be released at ISHLT 2011 0 None
2011-04-16 Opexa's Tovaxin Phase IIb study data in MS presented at AAN meeting 0 5
2011-04-15 Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis 0 None
2011-04-15 Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children 0 None
2011-04-15 Investigational Alzheimer's compounds may treat neuropathies 0 None
2011-04-15 Halozyme announces Aspart-PH20 study results in type 1 diabetes 0 None
2011-04-15 Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS 0 None
2011-04-15 QRxPharma receives new U.S. Patent for MoxDuo IR in treatment of acute pain 0 None
2011-04-15 Perampanel drug can effectively treat seizures in patients with epilepsy 0 None
2011-04-12 Yissum announces successful Docetaxel pre-clinical data in cancer 0 None
2011-04-12 Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting 0 None
2011-04-12 Sirolimus may help treat lymphangioleiomyomatosis in women 0 None
2011-04-12 Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma 0 5
2011-04-12 Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN 0 None
2011-04-12 Novel drug holds potential against resistant chronic myeloid leukemia 0 None
2011-04-12 Laquinimod drug greatly reduces number of relapses in patients with MS 0 2
2011-04-12 Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR 0 None
2011-04-11 NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma 0 None
2011-04-11 Vanda initiates Fanapt Phase I study in patients with schizophrenia 0 None
2011-04-11 Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency 0 None
2011-04-11 Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS 0 None
2011-04-11 The Lancet publishes VIVUS 56-week QNEXA study results in obesity 0 None
2011-04-11 Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria 0 None
2011-04-11 Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event 0 None
2011-04-11 New experimental drug can help treat peripheral neuropathy in cancer patients 0 3.5
2011-04-11 Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma 0 None
2011-04-11 Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain 0 None
2011-04-11 Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection 0 None
2011-04-11 Gilenya can reduce risk of disability progression in patients with RRMS 0 None
2011-04-11 Investigational drug effective for patients with obesity 0 None
2011-04-11 New study finds no significant benefit of bosentan against IPF 0 None
2011-04-08 Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer 0 None
2011-04-08 FDA grants tentative approval for Hi-Tech Pharmacal's generic Combigan ANDA 0 None
2011-04-08 ViroXis' IND for EISO-derived product to treat HPV skin warts receives FDA approval 0 None
2011-04-08 HALT-C trial reveals high mortality rates among patients with HCV 0 5
2011-04-08 Long-term delivery of CNTF slows loss of visual acuity caused by geographic atrophy 0 None
2011-04-08 Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema 0 None
2011-04-08 Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR 0 None
2011-04-08 Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting 0 None
2011-04-07 Positive top-line results from Roche's T-DM1 Phase II trial in HER2-positive MBC 0 None
2011-04-07 MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal 0 None
2011-04-07 Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting 0 None
2011-04-07 OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting 0 None
2011-04-07 Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting 0 None
2011-04-07 Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal 0 None
2011-04-07 VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting 0 None
2011-04-06 Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers 0 None
2011-04-06 ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours 0 None
2011-04-06 Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011 0 None
2011-04-06 Celldex presents CDX-1127 preclinical data against cancer at AACR meeting 0 None
2011-04-06 Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting 0 None
2011-04-06 J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism 0 None
2011-04-06 Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting 0 None
2011-04-06 Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting 0 None
2011-04-06 Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting 0 None
2011-04-06 Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia 0 None
2011-04-06 Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting 0 None
2011-04-05 ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers 0 None
2011-04-05 Incyte earns $15M milestone payment from Novartis for INCB28060 Phase I dose-escalation cancer trial 0 None
2011-04-05 R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development' 0 4.5
2011-04-05 RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients 0 5
2011-04-05 Aeterna Zentaris presents two posters on perifosine at AACR meeting 0 None
2011-04-05 OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting 0 None
2011-04-05 Synta presents ganetespib and elesclomol study data in cancer at AACR meeting 0 None
2011-04-05 Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting 0 None
2011-04-05 Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting 0 None
2011-04-05 Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia 0 None
2011-04-05 Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results 0 None
2011-04-05 Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting 0 None
2011-04-04 Daiichi Sankyo acquires Plexxikon 0 None
2011-04-04 Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients 0 None
2011-04-04 Aspirin usage associated with decrease in pancreatic cancer risk 0 None
2011-04-04 ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting 0 None
2011-04-04 Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting 0 None
2011-04-04 ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting 0 None
2011-04-04 Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting 0 None
2011-04-04 Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury 0 None
2011-04-04 Human immune system can help predict recurrence, overall breast cancer survival 0 None
2011-04-04 BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV 0 5
2011-04-04 BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV 0 None
2011-04-04 Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL 0 None
2011-04-04 Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer 0 None
2011-04-04 New data: Quadruple therapy can effectively treat patients with HCV 0 None
2011-04-04 New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability 0 None
2011-04-04 Positive results from GDC-0449 Phase II data against basal cell nevus syndrome 0 None
2011-04-02 Pfizer to present new investigational compounds data against cancer at AACR meeting 0 None
2011-04-02 Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting 0 None
2011-04-02 MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting 0 None
2011-04-02 Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting 0 None
2011-04-02 Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335 0 None
2011-04-02 Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress 0 None
2011-04-01 Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL 0 None
2011-04-01 Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting 0 None
2011-04-01 APEX-PD Phase III clinical study data to be presented at American Academy of Neurology Conference 0 None
2011-04-01 Obeticholic Acid safe and effective against Primary Biliary Cirrhosis 1 3.3
2011-04-01 Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery 0 None
2011-04-01 Novartis, Intercell to initiate Pseudomonas vaccine trial in ventilated ICU patients 0 None
2011-04-01 Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting 0 1.5
2011-04-01 CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury 0 None
2011-04-01 VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting 0 None
2011-04-01 Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas 0 None
2011-04-01 Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting 0 5
2011-04-01 Vertex announces final results from Phase 3 REALIZE study against HCV 0 None
2011-04-01 Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting 0 None
2011-04-01 Syndax to present entinostat data against cancer at AACR meeting 0 None
2011-04-01 Positive outcome from Orexo's OX51 initial pharmacokinetic trial to treat acute intensive pain 0 None
2011-04-01 Positive results from Intercept OCA Phase II trial in patients with PBC 0 None
2011-04-01 Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer 0 None
2011-03-31 Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus 0 None
2011-03-31 Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s 0 None
2011-03-31 FDA grants Nile Fast Track designation for cenderitide post-acute development program 0 None
2011-03-31 Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder 0 None
2011-03-31 Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C 0 None
2011-03-31 Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV 0 None
2011-03-31 NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV 0 None
2011-03-31 Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting 0 None
2011-03-31 Positive outcomes from imatinib trial in both older and younger patients with CML 0 None
2011-03-31 Glasgow Professor discusses about new approach for CML treatment at UK conference 0 None
2011-03-31 CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel 0 None
2011-03-31 Boceprevir drug can help cure hard-to-treat hepatitis C 0 None
2011-03-31 Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC 0 None
2011-03-31 Three-drug cocktail more effective against hepatitis C virus 0 None
2011-03-31 Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting 0 None
2011-03-30 MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF 0 None
2011-03-30 Amgen announces top-line results from motesanib Phase 3 trial against NSCLC 0 None
2011-03-30 BioSante completes patient enrollment in LibiGel Phase III trial against HSDD 0 None
2011-03-30 Pharmasset commences PSI-7977 Phase 2b study against HCV 0 None
2011-03-30 Columbia Labs' PROCHIEVE Phase III trial results to be published in online medical journal 0 None
2011-03-30 SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting 0 None
2011-03-30 Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV 0 None
2011-03-30 Positive results from Vertex VX-770 Phase 3 trial against CF 0 None
2011-03-30 Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis 0 None
2011-03-30 Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes 0 None
2011-03-29 New lung cancer drug starts human trials 0 None
2011-03-29 Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy 0 None
2011-03-29 Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit 0 None
2011-03-29 Keryx KRX-0401 trial data against colorectal cancer, multiple myeloma to be presented at AACR 0 None
2011-03-29 Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma 0 None
2011-03-29 International Phase II trial to study LY2181308 efficacy in patients with lung cancer 0 None
2011-03-29 CytRx to present bafetinib preclinical study results at AACR Annual Meeting 0 None
2011-03-29 Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting 0 None
2011-03-28 Dementia & Alzheimer’s drug trial with sleep hormone melatonin 0 None
2011-03-28 PHOENIX phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB 0 None
2011-03-28 ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown 0 None
2011-03-28 Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes 0 None
2011-03-28 Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center 0 None
2011-03-28 Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease 0 None
2011-03-28 Phase 2a study of DARA BioSciences KRN5500 in treatment of cancer pain reaches primary end-point 0 None
2011-03-28 Cancer drug Gleevec may hold promise against scleroderma: Study 0 5
2011-03-28 AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting 0 None
2011-03-28 NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS 0 None
2011-03-28 Genentech's Lucentis Phase III trials in DME meets primary endpoints 0 None
2011-03-25 XTL announces MinoGuard acquisition 0 None
2011-03-25 Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer 0 None
2011-03-25 Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients 0 None
2011-03-25 Isotechnika fourth quarter consolidated net loss increases to $2.42 million 0 None
2011-03-25 Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology 0 None
2011-03-25 Study examines regional analgesia effect on long-term outcomes in soldiers with combat injuries 0 None
2011-03-25 SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting 0 None
2011-03-25 Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke 0 None
2011-03-25 Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD 0 None
2011-03-25 Positive top-line results from POZEN's PA32540 Phase 1 study against cardiovascular disease 0 None
2011-03-25 Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers 0 None
2011-03-25 Clinical trial to determine whether Crestor can prevent new colon tumors after surgery 0 None
2011-03-25 Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis 0 None
2011-03-24 Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting 0 None
2011-03-24 Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD 0 None
2011-03-24 Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting 0 None
2011-03-24 Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients 0 None
2011-03-24 Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder 0 None
2011-03-24 Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective 0 None
2011-03-24 Oramed reports successful completion of ORMD-0801 oral insulin toxicity study 0 None
2011-03-24 KaloBios commences KB004 Phase 1 trial in patients with leukemia 0 None
2011-03-23 Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery 0 None
2011-03-23 MnSOD oral drug can protect against lung cancer radiation therapy 0 None
2011-03-23 Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment 0 None
2011-03-23 Jefferson begins patient recruitment for new clinical trail to prevent colon cancer 0 None
2011-03-23 ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting 0 None
2011-03-23 Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA 0 None
2011-03-23 Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes 0 None
2011-03-23 FDA approves Harvest's BMAC System IDE trial to treat non-reconstructable Critical Limb Ischemia 0 None
2011-03-23 Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients 0 None
2011-03-23 Cellerant commences CLT-008 Phase I/II trial in patients with leukemia 0 None
2011-03-23 Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis 0 5
2011-03-23 Astellas announces positive results from mirabegron phase III trials against OAB 0 5
2011-03-23 Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI 0 None
2011-03-22 Five year course of tamoxifen can offer long-term benefit for women with breast cancer 0 None
2011-03-22 Positive results from Meda's Dymista Phase III trial in patients with SAR 0 None
2011-03-22 Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting 0 None
2011-03-22 CSL Behring presents Hizentra study data against PI at AAAAI meeting 0 None
2011-03-22 Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting 0 None
2011-03-22 Polypill may serve as viable option for developing countries to treat CVD risk prevention 0 None
2011-03-22 ACE, ARB combination therapy may increase risk of kidney failure, death 0 None
2011-03-22 BMY's ipilimumab Phase III study against metastatic melanoma meets primary endpoint 0 None
2011-03-21 Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology 0 None
2011-03-21 Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer 0 None
2011-03-21 Curemark reaches targeted enrollment in CM-AT Phase III clinical trials for autism 0 None
2011-03-21 NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis 0 None
2011-03-21 FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections 0 None
2011-03-21 Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain 0 None
2011-03-21 NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza 0 None
2011-03-21 United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension 0 None
2011-03-21 Advanced Cell Technology reduces 2010 debt to less than $1 million 0 None
2011-03-21 Medicago launches clinical development of seasonal flu vaccine 0 None
2011-03-21 Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema 0 None
2011-03-21 XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD 0 None
2011-03-21 Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma 0 None
2011-03-21 CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma 0 None
2011-03-21 Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint 0 None
2011-03-19 BioMarin announces preliminary results from ADAPT in patients suffering from PKU 0 None
2011-03-19 The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence 0 None
2011-03-19 Quark Pharmaceuticals receives results from Phase 2 trial of PF-04523655 in patients with DME 0 None
2011-03-19 Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma 0 None
2011-03-18 Science journal publishes CYTK preclinical cardiac myosin activation research results 0 None
2011-03-18 KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction 0 None
2011-03-18 Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma 0 None
2011-03-18 FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease 0 None
2011-03-17 CytRx commences INNO-206 Phase 1b trial in advanced solid tumors 0 None
2011-03-17 PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting 0 None
2011-03-17 New lozenge clinical trial for dry mouth treatment 1 None
2011-03-17 HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers 0 None
2011-03-17 Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers 0 None
2011-03-17 Specific type of selenium supplement may help prevent cancer 0 None
2011-03-17 The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD 0 4
2011-03-16 Fibrocell Science submits azficel-T final study report to FDA 0 None
2011-03-16 RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold 0 None
2011-03-16 Cortex enters agreement with Biovail to regain AMPAKINE assets and rights 0 None
2011-03-16 NIH awards TriLink $100,000 Phase I SBIR Grant to develop Hot Start approach for Ligase Chain Reaction 0 None
2011-03-16 Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome 0 None
2011-03-16 Plexxikon selects Clinipace to manage 4 clinical trials for RA treatment 0 None
2011-03-16 AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation 0 None
2011-03-16 Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis 0 None
2011-03-16 iTherX commences ITX-5061 Phase 1b study in patients with HCV 0 None
2011-03-15 Apeiron in antitumor substances deal with Cleveland Clinic 0 None
2011-03-15 Anavex to commence phase I clinical trial in Alzheimer’s disease 0 None
2011-03-15 Additional research needed for oral PrEP to treat HIV 0 None
2011-03-15 CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial 0 None
2011-03-15 Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint 0 5
2011-03-15 Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy 0 None
2011-03-15 Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS 0 None
2011-03-15 Positive top-line results from IPX066 Phase III study in patients with PD 0 None
2011-03-14 Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas 0 None
2011-03-14 Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder 0 None
2011-03-14 Positive results from azide drug-loaded Emulsiphan preclinical toxicity study 0 None
2011-03-14 Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development 0 None
2011-03-14 KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism 0 None
2011-03-14 Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder 0 None
2011-03-14 Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides 0 None
2011-03-14 Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis 0 None
2011-03-14 ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV 0 None
2011-03-14 BioInvent commences BI-204 phase II study in patients with acute coronary syndrome 0 None
2011-03-14 Combination therapy may overcome Herceptin-resistant breast cancer 0 None
2011-03-12 Alzheimer's vaccine - First evidence for efficacy 0 5
2011-03-11 Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint 0 None
2011-03-11 Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints 0 None
2011-03-11 Inhibitex fourth quarter net loss increases to $7.0 million 0 None
2011-03-11 Synta fourth-quarter total collaboration revenue decreases to $3.0 million 0 None
2011-03-11 Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC 0 None
2011-03-11 Genentech announces positive outcomes from Lucentis Phase III trial against DME 0 None
2011-03-11 Sildenafil helps improve exercise performance in children with congenital heart disease 0 None
2011-03-10 Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults 0 None
2011-03-10 Positive results from exenatide phase 2 study in patients with type 2 diabetes 0 None
2011-03-10 Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma 0 None
2011-03-10 Idera reports $6.0 million net loss for fourth quarter 2010 0 None
2011-03-10 Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris 0 None
2011-03-10 Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases 0 None
2011-03-10 CTI announces final pixantrone clinical trial design for treatment of DLBCL 0 None
2011-03-10 FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids 0 None
2011-03-10 Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia 0 None
2011-03-10 TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis 0 None
2011-03-09 NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease 0 None
2011-03-09 Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease 0 5
2011-03-09 ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL 0 None
2011-03-09 Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting 0 None
2011-03-09 Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO 0 5
2011-03-09 Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study 0 None
2011-03-09 Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting 0 3
2011-03-09 FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly 0 None
2011-03-09 FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease 0 None
2011-03-09 Unique gene therapy to combat Parkinson's disease 0 None
2011-03-09 Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD 0 None
2011-03-08 Treatment with sildenafil significantly reduces RP in patients with scleroderma 0 None
2011-03-08 Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma 0 None
2011-03-08 Conflicts of interest overlooked in drug trial reviews: Study 0 None
2011-03-08 Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA 0 None
2011-03-08 Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions 0 None
2011-03-08 BMY to present new Phase II data on investigational hepatitis C compounds at ILC 0 None
2011-03-08 Fumaric acid salts may protect against Multiple Sclerosis 0 None
2011-03-08 New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts 0 1
2011-03-08 Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression 0 None
2011-03-07 Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer 0 None
2011-03-07 USPTO grants patent to Symphogen's Sym004 to treat solid tumors 0 None
2011-03-07 Duchenne Parent Project awards grant to AMT for DMD gene therapy 0 None
2011-03-07 TapImmune provides clinical development clarification based on March 1 Press Release 0 None
2011-03-05 Researchers use qMRI to confirm effect of CS treatment in patients with OA 0 None
2011-03-05 Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study 0 None
2011-03-05 Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints 0 None
2011-03-04 Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI 0 None
2011-03-04 Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75% 0 None
2011-03-04 BioSante vaccine increases median survival of resected pancreatic cancer patients 0 None
2011-03-04 Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo 0 None
2011-03-04 Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion 0 None
2011-03-04 Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL 0 None
2011-03-04 Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment 0 None
2011-03-03 Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA 0 None
2011-03-03 Clinical trials in Australia take too long– need uniform standards: Report 0 None
2011-03-03 Glenmark Generics granted final FDA approval for generic Xyzal ANDA 0 None
2011-03-03 Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA 0 None
2011-03-03 Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer 0 None
2011-03-03 Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV 0 None
2011-03-03 Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal 0 None
2011-03-03 Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes 0 None
2011-03-03 Lixte receives $244,479.25 U.S. government grant for QTDP program 0 None
2011-03-03 Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV 0 None
2011-03-03 Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine 0 None
2011-03-03 EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML 0 None
2011-03-03 Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack 0 None
2011-03-02 FDA accepts Handa's generic DEXILANT ANDA for review 0 None
2011-03-02 Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI 0 None
2011-03-02 Mylan confirms lawsuit relating to Estradiol Transdermal System ANDA 0 None
2011-03-02 Allergan initiates AGN-214868 Phase II trials in post herpetic neuralgia and overactive bladder 0 None
2011-03-02 Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder 0 None
2011-03-02 Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses 0 None
2011-03-02 Geron's hESC derived GRNCM1 halts remodeling process and preserves cardiac function in acute heart damage 0 None
2011-03-02 NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer 0 None
2011-03-02 OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea 0 None
2011-03-01 Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis 0 None
2011-03-01 Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL 0 None
2011-03-01 Tenofovir gel more effective than oral tablet for HIV treatment: Study 0 None
2011-03-01 Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI 0 None
2011-02-28 Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients 0 None
2011-02-28 TCD announces first patient treated in its TCD-717 Phase I trial 0 None
2011-02-28 ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer 0 None
2011-02-28 Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study 0 None
2011-02-28 Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty 0 None
2011-02-28 Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL 0 None
2011-02-28 Positive results from Trius torezolid Phase 1 lung study 0 None
2011-02-28 Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference 0 None
2011-02-28 MEPs, OETC visit new TB vaccine trial site to express support for candidate development 0 5
2011-02-28 Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder 0 None
2011-02-28 First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate 0 None
2011-02-28 Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference 0 None
2011-02-27 Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer 0 None
2011-02-27 Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer 0 None
2011-02-25 Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL 0 None
2011-02-25 Neoprobe's Lymphoseek Phase 2 study data published in Annals of Surgical Oncology 0 None
2011-02-25 Preclinical data of Zalicus sodium channel compound published in journal PAIN 0 None
2011-02-25 Medwell commits $2,000,000 investment in Mimetogen 0 None
2011-02-25 U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae 0 None
2011-02-25 Targets against MRSA in microgravity 0 None
2011-02-25 Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease 0 None
2011-02-25 Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection 0 None
2011-02-25 Radioactive tracing agent can identify tumor-draining sentinel nodes in breast cancer, melanoma patients 0 None
2011-02-25 The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases 0 3
2011-02-25 Enobia completes patient enrollment in ENB-0040 Phase II study for HPP 0 None
2011-02-25 Lux initiates pivotal voclosporin Phase 3 trial in non-infectious uveitis 0 None
2011-02-25 Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer 0 None
2011-02-25 Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells 0 None
2011-02-25 BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza 0 None
2011-02-24 PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections 0 None
2011-02-24 BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD 0 None
2011-02-24 Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP 0 None
2011-02-24 Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment 0 None
2011-02-24 Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF 0 None
2011-02-24 First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant 0 None
2011-02-23 Oncolytics completes patient enrollment in REOLYSIN trial to treat metastatic colorectal cancer 0 None
2011-02-23 PCI Biotech completes patient inclusion in PC-A11 phase I/II study to treat cancer 0 None
2011-02-23 Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure 0 None
2011-02-23 Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic 0 None
2011-02-23 Aeterna to present two novel anticancer compounds at Bio Partnering North America conference 0 None
2011-02-23 Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery 0 None
2011-02-23 ISCTM 7th annual meeting to discuss drug development based on amyloid hypothesis of Alzheimer's disease 0 None
2011-02-23 Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure 0 None
2011-02-23 Survey: 67% of pharma and biotech companies outsource more than half of all clinical trials 0 None
2011-02-23 Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology 0 None
2011-02-23 American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer 0 None
2011-02-23 Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD 0 4
2011-02-22 Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD 0 None
2011-02-22 TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes 0 None
2011-02-22 Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer 0 None
2011-02-22 KemPharm commences KP201 Phase 1 trial for pain 0 None
2011-02-22 Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California 0 None
2011-02-22 Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions 0 None
2011-02-22 Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema 0 None
2011-02-22 Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV 0 None
2011-02-21 Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia 0 None
2011-02-21 Synexus creates specialist vaccines team to help pharma and biotech companies 0 None
2011-02-20 Bangladesh cholera vaccine trial 0 None
2011-02-19 Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium 0 None
2011-02-19 Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease 0 None
2011-02-19 Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium 0 None
2011-02-19 EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial 0 5
2011-02-19 FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency 0 None
2011-02-19 Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting 0 4.5
2011-02-18 Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV 0 None
2011-02-18 Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial 0 None
2011-02-18 BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain 0 None
2011-02-18 Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences 0 None
2011-02-18 Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol 0 None
2011-02-18 FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera 0 None
2011-02-18 Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment 0 None
2011-02-17 Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD 0 None
2011-02-17 Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer 0 None
2011-02-17 Clinical trial finds atorvastatin may inhibit HIV progression, help in infection's management 0 None
2011-02-17 FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma 0 None
2011-02-17 Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease 0 None
2011-02-17 Oncolytics begins enrollment in 2-Arm carboplatin Phase II randomized study for pancreatic cancer 0 None
2011-02-16 Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial 0 None
2011-02-16 Endologix announces initial PEVAR Trial presentation at 2011 iCON annual meeting 0 None
2011-02-16 Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL 0 2
2011-02-15 The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza 0 4
2011-02-15 Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis 0 None
2011-02-15 Almac's Director plans to speak on adaptive trial designs at CTS Europe conference 0 None
2011-02-15 Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters 0 None
2011-02-15 Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint 0 None
2011-02-14 Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency 0 None
2011-02-14 FDA waives NDA filing fee for Antares' Anturol NDA 0 None
2011-02-14 FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS 0 None
2011-02-14 Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma 0 5
2011-02-14 Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis 0 None
2011-02-14 OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer 0 None
2011-02-14 Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea 0 2
2011-02-14 Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol 0 None
2011-02-14 SynthRx to become wholly-owned subsidiary of ADVENTRX 0 None
2011-02-14 Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis 0 None
2011-02-14 Phase III RISE study of Lucentis for DME meets primary endpoint 0 None
2011-02-14 Last patient in EU Diamyd Phase III clinical study completes 15-month visit for type 1 diabetes 0 None
2011-02-14 JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery 0 None
2011-02-13 Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD 0 None
2011-02-11 FDA grants Inhibitex Fast Track Designation for INX-189 in treatment of chronic hepatitis C viral infection 0 None
2011-02-11 Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF 0 None
2011-02-10 Medivir initiates phase 1a clinical trial of TMC649128 for chronic HCV infection 0 None
2011-02-10 Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer 0 None
2011-02-10 Gilead resubmits NDA for single-tablet regimen of Truvada/TMC278 0 None
2011-02-10 Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain 0 None
2011-02-10 EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness 0 5
2011-02-10 Vical 2010 net loss increases to $30.4 million 0 None
2011-02-10 Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors 0 None
2011-02-10 Diamyd's NP2 Enkephalin Phase II study in cancer pain posted on ClinicalTrials.gov 0 None
2011-02-10 Hormone 17-Hydroxyprogesterone does not reduce rate of preterm delivery in twin pregnancies: Study 0 None
2011-02-10 Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial 0 None
2011-02-09 Everolimus phase III study shows improved progression-free survival in patients with pNET 0 None
2011-02-09 Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes 0 None
2011-02-09 PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI 0 None
2011-02-09 GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic 0 None
2011-02-09 CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders 0 3
2011-02-09 A.P. Pharma provides update on response to APF530 Complete Response Letter 0 None
2011-02-09 R-Tech commences RK-023 Phase I study for treatment of eyelash hypotrichosis 0 None
2011-02-09 Gentium completes Defibrotide clinical studies, plans to file for regulatory approval 0 None
2011-02-09 Medicago granted FDA clearance for clinical development of seasonal flu vaccine 0 None
2011-02-09 Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients 0 None
2011-02-08 CytRx's bafetinib helps reduce skeletal complications in cancer patients 0 None
2011-02-08 Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI 0 None
2011-02-08 Scientists develop low cost, nanometer-sized drug to treat chronic wounds 0 None
2011-02-08 Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint 0 5
2011-02-08 Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics 0 None
2011-02-08 Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010 0 None
2011-02-07 PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors 0 None
2011-02-07 Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer 0 None
2011-02-07 AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder 0 None
2011-02-07 The Lancet journal publishes BENLYSTA BLISS-52 study against SLE 0 None
2011-02-07 Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN 0 None
2011-02-05 Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology 0 None
2011-02-05 Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA 0 None
2011-02-04 Anacor initiates dosing in AN2728 Phase 2b trial for psoriasis 0 None
2011-02-04 Positive results from Photocure's Allumera RevitAll study to improve skin's appearance 0 None
2011-02-04 EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal 0 None
2011-02-04 Positive results from KYTHERA's ATX-101 Phase IIb study for reduction of submental fat 0 None
2011-02-04 FDA sets new PDUFA date for AstraZeneca's ticagrelor 0 None
2011-02-04 CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds 0 None
2011-02-04 MicroCHIPS commences first hPTH clinical study in women with osteoporosis 0 None
2011-02-04 Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME 0 None
2011-02-04 Positive top-line results from ILUVIEN Phase 3 trial in patients with DME 0 5
2011-02-03 Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease 0 None
2011-02-03 Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers 0 None
2011-02-03 New England Journal publishes fidaxomicin Phase 3 trial results against CDI 0 5
2011-02-03 Inspiration presents IB1001 PK data for treatment of hemophilia B 0 None
2011-02-03 First therapeutic vaccine designed from dendritic cells of patient achieves significant response 0 None
2011-02-03 Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV 0 None
2011-02-03 Fidaxomicin demonstrates 45% reduction in recurrences vs. existing treatment for C. difficile infection 0 None
2011-02-03 Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI 0 None
2011-02-03 Inspiration presents IB1001 PK data at European haemophilia congress 0 None
2011-02-03 Merck announces publication of GARDASIL pivotal Phase III study data in NEJM 0 1
2011-02-03 Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin 0 None
2011-02-03 FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate 0 None
2011-02-03 ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM 0 None
2011-02-03 Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC 0 None
2011-02-03 Positive results from Factor IX-CTP comparative study in hemophilic mice 0 None
2011-02-02 EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer 0 None
2011-02-02 Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders 0 None
2011-02-02 DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011 0 None
2011-02-02 Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer 0 None
2011-02-02 FDA to inspect Lannett's manufacturing facility for review of Morphine Sulfate NDA 0 None
2011-02-02 Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes 0 None
2011-02-02 FDA issues Complete Response Letter for approval of Eisai's rabeprazole sodium extended-release capsules 0 None
2011-02-02 Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis 0 5
2011-02-01 BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome 0 3
2011-02-01 Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial 0 None
2011-02-01 Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine 0 None
2011-02-01 Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA 0 None
2011-02-01 Discovery Labs provides expanded update on efforts to gain FDA marketing authorization for Surfaxin in RDS 0 None
2011-02-01 AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma 0 5
2011-02-01 Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment 0 None
2011-02-01 Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief 0 None
2011-02-01 Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease 0 None
2011-02-01 FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma 0 None
2011-01-31 VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers 0 None
2011-01-31 Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis 0 None
2011-01-31 GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS 0 None
2011-01-31 Scientists to commence new DNA vaccine trial for use in patients with leukemia 0 None
2011-01-31 Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial 0 None
2011-01-29 Phase III study shows tapentadol ER relieves chronic pain associated with DPN 0 None
2011-01-28 Naprosyn used in Iroko's Phase I pharmacokinetic study of naproxen 0 None
2011-01-28 Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint 0 None
2011-01-28 Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents 0 1
2011-01-28 Cetero Research completes 20,000th early-phase clinical study 0 None
2011-01-28 Arena reduces workforce by 25% and provides update on lorcaserin 0 None
2011-01-28 Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting 0 None
2011-01-28 Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis 0 5
2011-01-28 Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal 0 5
2011-01-27 Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer 0 None
2011-01-27 Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis 0 None
2011-01-27 Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain 0 None
2011-01-27 Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion 0 None
2011-01-26 ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis 1 None
2011-01-26 Anadys begins dosing in ANA598 Phase IIb study for hepatitis C 0 None
2011-01-25 FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine 0 None
2011-01-25 Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia 0 None
2011-01-25 Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial 0 None
2011-01-25 Diamyd Medical reports first quarter group total net sales of MSEK 144.5 0 None
2011-01-25 PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011 0 None
2011-01-25 Eisai to seek marketing authorization for perampanel in the U.S. and EU 0 None
2011-01-25 Eisai's eritoran ACCESS study in severe sepsis does not meet primary endpoint 0 None
2011-01-25 Diamyd Medical to report European Phase III trial results for type 1 diabetes 0 None
2011-01-25 Promising results from TheraTears Nutrition pilot trial in dry eye patients 1 None
2011-01-24 Unrealistic optimism appears common in early cancer trials 0 None
2011-01-24 Furiex's MuDelta for diarrhea-predominant irritable bowel syndrome receives FDA Fast Track designation 0 None
2011-01-24 ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011 0 5
2011-01-24 Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer 0 None
2011-01-24 Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry 0 None
2011-01-24 Senesco files SNS01-T IND for treatment of multiple myeloma 0 None
2011-01-24 Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer 0 None
2011-01-24 Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis 0 4
2011-01-24 Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis 0 None
2011-01-24 R-Tech Ueno announces completion of RK-023 Phase 2a study for androgenetic alopecia 0 None
2011-01-24 SuppreMol completes successful pre-IND meeting with U.S. FDA 0 5
2011-01-23 FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer 0 None
2011-01-21 Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer 0 5
2011-01-21 Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011 0 None
2011-01-21 Sunshine and Binghamton University enter research agreement for cancer compound 0 None
2011-01-21 MedImmune announces MEDI-573 preclinical results against many solid tumors 0 None
2011-01-21 Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D 0 None
2011-01-21 Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117 0 4
2011-01-21 MGH Bipolar CHOICE trial to evaluate effectiveness of new medications compared to lithium 0 None
2011-01-21 Positive results from nimotuzumab Phase II study for gastric cancer 0 5
2011-01-21 ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer 0 None
2011-01-20 Preliminary top-line results from levomilnacipran Phase III study for MDD 0 None
2011-01-20 FDA accepts Vertex's telaprevir NDA for six-month Priority Review 0 4.8
2011-01-20 Cognition Therapeutics closes $2.5 million Series A1 financing 0 None
2011-01-20 FDA grants Soligenix Orphan Drug Designation to RiVax for prevention of ricin intoxication 0 None
2011-01-20 Chelsea reports top-line data from Phase III NORTHERA extension study in NOH 0 None
2011-01-20 ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma 0 None
2011-01-20 Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study 0 None
2011-01-20 FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology 0 None
2011-01-20 Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma 0 None
2011-01-20 Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients 0 None
2011-01-20 4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer 0 None
2011-01-20 Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl 0 None
2011-01-20 FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review 0 None
2011-01-20 GSK and Prosensa commence GSK2402968 Phase III study in DMD 0 4
2011-01-20 Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease 0 None
2011-01-20 Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia 0 None
2011-01-19 Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia 0 None
2011-01-19 Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development 0 None
2011-01-19 Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas 0 None
2011-01-19 New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux 0 None
2011-01-19 RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma 0 None
2011-01-19 Arrowhead increases ownership in Calando's outstanding equity to 79% 0 None
2011-01-19 Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma 0 1
2011-01-19 UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients 0 None
2011-01-18 NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer 0 None
2011-01-18 Alexza completes FDA review for AZ-004 NDA 0 None
2011-01-18 RTS,S offers 46 percent protection against malaria for at least 15 months after vaccination, Study finds 0 None
2011-01-18 Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV 0 None
2011-01-17 Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain 0 None
2011-01-14 Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial 0 4.3
2011-01-14 Merck announces changes in vorapaxar clinical studies 0 None
2011-01-13 Adjunctive lacosamide reduces seizures and improves responder rates 0 None
2011-01-13 BioCryst reports positive results from peramivir Phase 3 study in influenza 0 None
2011-01-13 BP-lowering medications provide long-term benefit of reducing death risk from cardiovascular disease 0 None
2011-01-13 FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis 0 3
2011-01-13 MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma 0 None
2011-01-13 Researchers launch estrogen therapy trial to study depression, cardiovascular illness in women 0 None
2011-01-13 TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers 0 None
2011-01-13 Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer 0 None
2011-01-12 AstraZeneca, CANCER RESEARCH UK enter strategic alliance to conduct experimental cancer drug trials 0 None
2011-01-12 GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease 0 5
2011-01-12 Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC 0 None
2011-01-12 Scientists find way to prevent early stage pancreatic cancer in research models 0 5
2011-01-12 Epigenetic therapy holds promise for cancer management 0 None
2011-01-12 UH, Case Western University commence clinical trial for bipolar disorder 0 1
2011-01-11 Rib-X raises $20M to support development of broad spectrum antibiotics pipeline 0 None
2011-01-11 FemmePharma completes FP 1097 Phase II clinical trial in women with OAB 0 None
2011-01-11 SciClone initiates phase 2b study of SCV-O7 for oral mucositis 0 None
2011-01-11 ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis 0 None
2011-01-11 Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML 0 None
2011-01-11 Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma 0 1
2011-01-11 Study supports use of telomerase inhibitors for treatment of childhood cancers 0 5
2011-01-11 Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure 0 None
2011-01-11 TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders 0 None
2011-01-11 DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent 0 None
2011-01-11 Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV 0 None
2011-01-11 Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval 0 None
2011-01-11 NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome 0 None
2011-01-11 LibiGel may be the first FDA approved product to treat HSDD in menopausal women 0 5
2011-01-10 Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia 0 5
2011-01-10 Celator, Cephalon extend cancer research agreement 0 None
2011-01-10 Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program 0 None
2011-01-10 Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea 0 None
2011-01-10 Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation 0 None
2011-01-10 Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy 0 None
2011-01-10 Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer 0 None
2011-01-10 Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study 0 None
2011-01-10 FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer 0 None
2011-01-10 KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat 0 3
2011-01-10 Positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C virus 0 None
2011-01-10 FDA, EMA accept boceprevir for expedited review 0 None
2011-01-10 Positive PK study results from ECLIPSE trial against cardiovascular disease 0 None
2011-01-10 Positive results form INX-189 Phase 1b trial against hepatitis C virus 0 5
2011-01-09 AFQ056 drug improves symptoms in Fragile X patients: Study 0 None
2011-01-07 MedImmune announces in-licensing agreement with Amgen for IL-1 pathway targeting novel monoclonal antibody 0 None
2011-01-07 Synergy's plecanatide Phase II/III trial to begin in second quarter 2011 0 None
2011-01-07 Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen 0 None
2011-01-07 Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses 0 5
2011-01-07 Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction 0 None
2011-01-07 BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer 0 None
2011-01-07 Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs 0 None
2011-01-07 Plexxikon, Genentech enter PLX4032 co-promotion agreement 0 None
2011-01-07 ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly 0 None
2011-01-07 Positive results from LifeCycle Pharma's LCP-Tacro comparative trial in de novo liver transplant patients 0 None
2011-01-07 Athersys completes patient enrollment in MultiStem Phase I study for leukemia 0 None
2011-01-07 Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan 0 None
2011-01-07 Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases 0 None
2011-01-07 Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol 0 None
2011-01-07 CeNeRx commences TriRima Phase II trial for treatment resistant depression 0 None
2011-01-06 Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis 0 None
2011-01-06 Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy 0 None
2011-01-06 MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer 0 None
2011-01-06 Choosing between EGFR therapeutic options in metastatic colorectal cancer 0 None
2011-01-06 Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211 0 2
2011-01-06 Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV 0 None
2011-01-06 Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer 0 None
2011-01-06 Positive topline results from ZGN-433 Phase 1b study in obesity patients 0 4.5
2011-01-06 Insite Vision announces completion of patient enrollment in ISV-303 Phase 1/2 trial for post surgical ocular pain, inflammation 0 None
2011-01-06 DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes 0 None
2011-01-05 Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis 0 None
2011-01-05 SuperGen initiates enrollment in first human trial of SGI-110 in MDS and AML 0 1
2011-01-05 Alnylam presents ALN-VSP Phase I trial results for liver cancer 0 None
2011-01-05 Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors 0 None
2011-01-05 Spectrum submits FUSILEV sNDA for treatment of colorectal cancer 0 None
2011-01-05 FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention 0 None
2011-01-05 Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease 0 None
2011-01-04 Anadys begins ANA598 Phase IIb study for hepatitis C 0 None
2011-01-04 FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial 0 None
2011-01-04 Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer 0 None
2011-01-03 Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism 0 None
2011-01-03 FDA authorizes Juventas' JVS-100 Phase II clinical trial for critical limb ischemia 0 None
2011-01-03 Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment 0 None

Total

2022 posts
46 comments
252 raters